
(
  (S
    (NP (NN Transforming) (NN growth) (JJ factor-β-induced) (JJ regulatory) (NN T) (NNS cells))
    (VP (VBP referee)
      (NP
        (NP
          (ADJP (JJ inflammatory)))
        (CC and)
        (NP (JJ autoimmune) (NNS diseases))))))

(
  (S
    (NP (NN Abstract))))

(
  (S
    (S
      (NP
        (ADJP (RB Naturally) (VBG occurring))
        (JJ CD4+CD25+) (JJ regulatory) (NN T) (NNS cells))
      (VP (VBP mediate)
        (NP
          (NP (JJ immune) (NN suppression))
          (S
            (VP (TO to)
              (VP (VB limit)
                (NP
                  (NP (NN immunopathogenesis))
                  (VP (VBN associated)
                    (PP (IN with)
                      (NP
                        (NP (JJ chronic) (NN inflammation))
                        (, ,)
                        (NP (JJ persistent) (NNS infections))
                        (CC and)
                        (NP (JJ autoimmune) (NNS diseases))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (PRP$ Their) (NN mode))
        (PP (IN of)
          (NP (NN suppression))))
      (VP
        (VP (VBZ is)
          (ADJP
            (ADJP (JJ contact-dependent))
            (, ,)
            (ADJP (JJ antigen-nonspecific))))
        (CC and)
        (VP (VBZ involves)
          (NP
            (NP (DT a) (JJ nonredundant) (NN contribution))
            (PP (IN from)
              (NP
                (NP
                  (NP (DT the) (NN cytokine) (NN transforming) (NN growth) (NN factor))
                  (PRN (-LRB- -LRB-)
                    (NP (NN TGF))
                    (-RRB- -RRB-)))
                (NN -β)))))))
    (. .)))

(
  (S
    (S (RB Not)
      (ADVP (RB only))
      (VP (MD can)
        (ADVP (RB TGF-β))
        (VP (VB mediate)
          (NP
            (NP (NN cell–cell) (NN suppression))
            (PP (IN between)
              (NP
                (NP (DT the) (JJ regulatory) (NN T) (NNS cells))
                (CC and)
                (NP (NN CD4+CD25-)
                  (CC or)
                  (JJ CD8+) (NN T) (NNS cells))))))))
    (, ,)
    (CC but)
    (S
      (NP (JJ new) (NN evidence))
      (ADVP (RB also))
      (VP (VBZ reveals)
        (NP
          (NP (PRP$ its) (NN role))
          (PP (IN in)
            (NP
              (NP (DT the) (NN conversion))
              (PP (IN of)
                (NP (NN CD4+CD25-) (NN T) (NNS cells))))))
        (, ,)
        (PP
          (ADVP (RB together))
          (IN with)
          (NP (NN TCR) (NN antigen) (NN stimulation)))
        (, ,)
        (PP (IN into)
          (NP (DT the) (JJ regulatory) (NN phenotype)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Elemental))
        (PP (TO to)
          (NP (DT this) (NN conversion) (NN process))))
      (VP (VBZ is)
        (NP
          (NP (NN induction))
          (PP (IN of)
            (NP
              (NP (NN expression))
              (PP (IN of)
                (NP
                  (NP (DT the) (NN forkhead) (NN transcription) (NN factor))
                  (, ,)
                  (NP (NN Foxp3)))))))))
    (. .)))

(
  (S
    (NP
      (NP (DT This) (JJ context-dependent) (NN coercion))
      (PP (IN of)
        (NP (JJ naive) (JJ CD4+) (NN T) (NNS cells)))
      (PP (IN into)
        (NP
          (NP (DT a) (JJ powerful) (NN subset))
          (PP (IN of)
            (NP (JJ regulatory) (NNS cells))))))
    (VP (VBZ provides)
      (NP
        (NP (DT a) (NN window))
        (PP (IN into)
          (NP
            (NP (JJ potential) (NN manipulation))
            (PP (IN of)
              (NP (DT these) (NNS cells))))))
      (S
        (VP (TO to)
          (VP (VBP orchestrate)
            (NP (JJ therapeutic) (NN intervention))
            (PP (IN in)
              (NP
                (NP (NNS diseases))
                (VP (VBN characterized)
                  (PP (IN by)
                    (NP (JJ inadequate) (NN suppression))))))
            (, ,)
            (PP (RB as) (RB well) (IN as)
              (NP
                (NP (DT a) (JJ promising) (NN means))
                (PP (IN of)
                  (S
                    (VP (VBG controlling)
                      (NP
                        (NP (JJ pathologic) (NNS situations))
                        (SBAR
                          (WHPP (IN in)
                            (WHNP (WDT which)))
                          (S
                            (NP (JJ excessive) (NN suppression))
                            (VP (VBZ dominates))))))))))))))
    (. .)))

(
  (S
    (NP (NN Introduction))))

(
  (S
    (S
      (NP (JJ Autoimmune) (NNS diseases))
      (VP (VBP are)
        (VP (VBN characterized)
          (PP (IN by)
            (NP
              (NP (DT a) (NN loss))
              (PP (IN of)
                (NP
                  (NP (NN regulation))
                  (PP (IN of)
                    (NP (NN T) (NN cell)
                      (NP
                        (NP (NN growth))
                        (CC and)
                        (NP (NN activation)))))))))
          (, ,)
          (PP (IN with)
            (NP
              (NP (JJ resultant) (JJ overexuberant) (NN inflammation))
              (CC and)
              (NP (NN tissue) (NN destruction)))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Although)
        (S
          (NP
            (NP (NN T) (NN cell) (NNS responses))
            (PP (TO to)
              (NP (JJ foreign) (NNS antigens))))
          (VP (VBP are)
            (ADJP (JJ essential)
              (PP (TO to)
                (NP
                  (NP (PRP$ our) (NN protection))
                  (PP (IN from)
                    (NP
                      (NP (DT a) (NN plethora))
                      (PP (IN of)
                        (NP
                          (NP
                            (ADJP (RB potentially) (JJ pathogenic))
                            (NNS agents))
                          (CC and)
                          (NP (NNS microbes))))))))))))
      (, ,)
      (NP
        (NP (NN T) (NN cell) (NNS responses))
        (PP (TO to)
          (NP (NN self) (NNS antigens))))
      (VP (MD can)
        (VP (VB be)
          (ADJP (RB overtly) (JJ deleterious)))))
    (. .)))

(
  (S
    (S
      (SBAR (IN As)
        (S
          (NP
            (NP (DT the) (NN signaling) (NNS pathways))
            (VP (VBN associated)
              (PP (IN with)
                (NP (NN T) (NN cell) (NN activation)))))
          (VP (VBP continue)
            (S
              (VP (TO to)
                (VP (VB be)
                  (ADJP (JJ illuminated))))))))
      (, ,)
      (NP (EX there))
      (VP (VBZ is)
        (ADVP (RB also))
        (NP
          (NP (DT an) (VBG emerging) (NN excitement))
          (PP (IN about)
            (NP
              (NP
                (ADJP (RB naturally) (VBG occurring))
                (JJ opposing) (NNS forces))
              (SBAR
                (WHNP (WDT that))
                (S
                  (VP (MD can)
                    (VP (VB exert)
                      (NP (NN control))
                      (PP (IN over)
                        (NP (JJ antigen-activated) (NN T) (NNS cells))))
                    (S
                      (VP (TO to)
                        (VP (VB prevent)
                          (NP
                            (NP (NN reactivity))
                            (PP (TO to)
                              (NP (NN self)))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Suppressor) (NN T) (NNS cells))
        (, ,)
        (VP (VBN implicated)
          (PP (IN in)
            (NP
              (NP
                (NP (DT this) (JJ regulatory) (NN process))
                (NNS decades))
              (ADVP (RB ago)))))
        (, ,))
      (VP
        (VP (VBP fell)
          (PP (IN into)
            (NP (NN ill) (NN repute))))
        (CC but)
        (VP (VBP have)
          (ADVP (RB recently))
          (VP (VBN re-emerged)
            (PP
              (CONJP (RB not) (RB only))
              (PP (IN as)
                (NP (DT a) (JJ real) (NN population)))
              (CC but)
              (PP (IN as)
                (NP
                  (NP (DT a) (NN population))
                  (ADJP (JJ crucial)
                    (PP (TO to)
                      (NP
                        (NP (JJ immune) (NN homeostasis))
                        (, ,)
                        (NP
                          (NP (NN maintenance))
                          (PP (IN of)
                            (NP (NN tolerance))))
                        (, ,)
                        (CC and)
                        (NP
                          (NP (NN prevention))
                          (PP (IN of)
                            (NP
                              (NP (DT the) (NN onset))
                              (PP (IN of)
                                (NP (JJ autoimmune) (NN disease))))))))))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP (PRP$ Their) (NN existence))
        (VP (VBZ is)
          (ADVP (RB no) (RBR longer))
          (PP (IN in)
            (NP (NN question)))))
      (, ,)
      (CC but)
      (S
        (PP (JJ true) (TO to)
          (NP (PRP$ their) (NN history)))
        (NP
          (NP
            (NP (DT these) (NNS cells))
            (, ,)
            (NP
              (NP (PRP$ their) (NN origin))
              (, ,)
              (NP (NN generation))
              (, ,)
              (CC and)
              (NP (NNS mechanisms))))
          (PP (IN of)
            (NP (NN action))))
        (VP (VBP have)
          (VP (VBN generated)
            (NP (JJ considerable) (NN controversy))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Recognition))
      (PP (IN of)
        (NP
          (NP (DT the) (JJ potential) (NN impact))
          (PP (IN of)
            (NP (DT these) (NNS cells)))
          (PP (IN in)
            (NP (JJ clinical) (JJ cellular) (NN therapy))))))
    (VP (VBZ has)
      (VP (VBN driven)
        (NP
          (NP (DT a) (JJ rapid) (NN expansion))
          (PP (IN of)
            (NP (DT the) (NN field))))
        (SBAR (IN in) (NN order) (TO to)
          (S
            (VP
              (VP (VB understand))
              (CC and)
              (VP (VBP manipulate)
                (NP
                  (NP (DT the) (JJ regulatory) (NN T) (NN cell) (NN population))
                  (S
                    (VP (TO to)
                      (VP (VB devise)
                        (NP
                          (NP (NNS strategies))
                          (PP (TO to)
                            (NP
                              (NP (NN control) (NN autoimmunity))
                              (, ,)
                              (NP (NN transplantation) (NN tolerance))
                              (, ,)
                              (NP (NN tumor) (NN immunity))
                              (, ,)
                              (NP (NN allergy))
                              (CC and)
                              (NP (JJ infectious) (NNS diseases))
                              (, ,)
                              (ADVP (RB particularly))
                              (NP (NN HIV)))))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CD One))
        (PP (IN of)
          (S
            (VP
              (ADVP (DT the) (RBS most) (RB intensely))
              (VBN studied)
              (PP (IN of)
                (NP
                  (NP (DT the) (JJ heterogeneous) (NN family))
                  (PP (IN of)
                    (NP (JJ regulatory) (NN T) (NNS cells)))))))))
      (VP (VBZ is)
        (NP
          (NP (DT a) (NN population))
          (PP (IN of)
            (NP
              (NP (JJ CD4+) (NN T) (NNS cells))
              (VP
                (VP
                  (ADVP (RB constitutively))
                  (VBG expressing)
                  (NP
                    (NP (NN CD25) (-LRB- -LRB-) (CD IL-2Rα) (-RRB- -RRB-))
                    (, ,)
                    (VP (VBN found)
                      (PP
                        (PP (IN in)
                          (NP (NN thymus)))
                        (CC and)
                        (PP (IN in)
                          (NP (JJ peripheral) (JJ lymphoid) (NNS organs)))))
                    (, ,)))
                (CC and)
                (VP (VBG comprising)
                  (NP
                    (NP
                      (QP (CD 5) (TO to) (CD 10))
                      (NN %))
                    (PP (IN of)
                      (NP (DT the) (JJ total) (JJ CD4+) (NN T) (NNS cells))))
                  (PP (IN in)
                    (NP
                      (NP (NNS mice))
                      (CC and)
                      (NP (NNS humans) (CD -LSB-1-5) (-RRB- -RSB-)))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN On) (DT the) (NN basis) (IN of)
        (NP (PRP$ their) (JJ unique) (JJ functional) (NNS properties)))
      (, ,)
      (NP
        (NP (DT this)
          (ADJP
            (ADJP (JJ small))
            (CC but)
            (ADJP (JJ powerful)))
          (NN population))
        (PP (IN of)
          (NP (NN T) (NNS cells))))
      (VP (VBZ has)
        (VP (VBN been)
          (NP
            (NP (JJ dubbed) (JJ CD4+CD25+) (JJ regulatory) (NN T) (NNS cells))
            (PRN (-LRB- -LRB-)
              (NP (NN Treg))
              (-RRB- -RRB-))))))
    (. .)))

(
  (S
    (S
      (PP (IN In) (NN contrast) (TO to)
        (NP (NN CD4+CD25-) (NN T) (NNS cells)))
      (, ,)
      (NP
        (ADJP (RB freshly) (VBN isolated))
        (NN CD4+CD25+) (NNS Treg))
      (VP (VBP are)
        (ADJP (JJ anergic)
          (PP (TO to)
            (NP (NN TCR) (NN stimulation)))
          (ADVP (FW in) (FW vitro)))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (SBAR (IN once)
        (S
          (VP (VBN activated))))
      (, ,)
      (NP (DT these) (NNS Treg))
      (VP
        (VP (VBP are)
          (NP (JJ robust) (NNS suppressors)))
        (CC and)
        (VP (MD can)
          (VP (VB mediate)
            (NP
              (NP (DT the) (NN inhibition))
              (PP (IN of)
                (NP (NN CD4+CD25-) (NN responder) (NN T) (NNS cells))))
            (PP (IN by) (NNS means) (IN of)
              (NP
                (NP (DT a) (JJ cell-contact-dependent) (NN mechanism))
                (VP (VBG involving)
                  (NP
                    (NP
                      (NP (NN transforming) (NN growth) (NN factor))
                      (PRN (-LRB- -LRB-)
                        (NP (NN TGF))
                        (-RRB- -RRB-)))
                    (NN -β) (NN -LSB-6-9))))))))
      (-RRB- -RSB-)
      (PRN (-LRB- -LRB-)
        (NP (NNP Fig.) (CD 1))
        (-RRB- -RRB-)))
    (. .)))

(
  (S
    (SBAR (IN Although)
      (S
        (NP
          (NP (DT the) (NN role))
          (PP (IN of)
            (NP (NN TGF-β))))
        (VP (VBZ has) (RB not)
          (ADVP (RB yet))
          (VP (VBN been)
            (NP
              (ADJP (RB universally) (VBN accepted))
              (NN -LSB-10,11))))
        (-RRB- -RSB-)))
    (, ,)
    (NP
      (NP (DT the) (NN preponderance))
      (PP (IN of)
        (NP (NN evidence))))
    (VP (VBZ has)
      (VP (VBN solidified)
        (NP
          (NP (DT a) (NN contribution))
          (PP (IN from)
            (NP (NN TGF-β)))
          (PP (IN in)
            (NP (DT the) (JJ regulatory) (NN process) (NN -LSB-6-8,12-15)))
          (-RRB- -RSB-))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN essentiality))
        (PP (IN of)
          (NP (DT this) (JJ endogenous) (NN population)))
        (PP (IN in)
          (S
            (VP (VBG protecting)
              (NP (DT the) (NN host))
              (PP (IN from)
                (NP
                  (NP (JJ disproportionate) (NN T) (NN cell) (NN activation))
                  (CC and)
                  (NP (JJ autoreactive) (NN effector) (NNS cells))))))))
      (VP (VBZ is)
        (VP (VBN underscored)
          (PP (CC both)
            (PP (IN in)
              (NP (JJ experimental) (NNS models)))
            (CC and)
            (PP (IN in)
              (NP
                (NP (NNS humans))
                (SBAR
                  (WHPP (IN in)
                    (WHNP (WDT which)))
                  (S
                    (NP
                      (NP
                        (NP (DT the) (NNS numbers))
                        (CC and/or)
                        (NP (NN function)))
                      (PP (IN of)
                        (NP (NN Treg))))
                    (VP (VBP are)
                      (VP (VBN compromised)
                        (NP (CD -LSB-6,10,16-20) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (NNS mice)))
    (, ,)
    (NP
      (NP (NN depletion))
      (PP (IN of)
        (NP (NN CD4+CD25+) (NN T) (NNS cells)))
      (PP (IN by)
        (NP (JJ neonatal) (-LRB- -LRB-) (NN day) (CD 3) (-RRB- -RRB-) (NN thymectomy))))
    (VP (VBZ leads)
      (PP (TO to)
        (NP
          (NP (JJ spontaneous) (NN development))
          (PP (IN of)
            (NP
              (NP (JJ organ-specific) (JJ autoimmune) (NNS diseases))
              (, ,)
              (PP (VBG including)
                (NP
                  (NP (JJ autoimmune) (NN thyroiditis))
                  (, ,)
                  (NP (NN gastritis))
                  (, ,)
                  (CC and)
                  (NP (NN wasting) (NN -LSB-19))
                  (-RRB- -RSB-)))
              (, ,)
              (SBAR
                (WHNP (WDT which))
                (S
                  (VP (MD can)
                    (VP (VB be)
                      (VP (VBN reversed)
                        (PP (IN by)
                          (NP
                            (NP (JJ adoptive) (NN transfer))
                            (PP (IN of)
                              (NP (NN Treg) (NN -LSB-21) (-RRB- -RSB-)))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NNS Treg))
      (VP (VBP are)
        (ADJP (JJ pivotal)
          (PP (IN in)
            (NP
              (NP (DT the) (NN protection))
              (PP (IN of)
                (NP (JJ lymphopenic) (NNS mice)))
              (PP (IN from)
                (NP
                  (NP (VBN induced) (JJ inflammatory) (NN bowel) (NN disease))
                  (, ,)
                  (NP (JJ experimental) (JJ autoimmune) (NN encephalomyelitis))
                  (, ,)
                  (NP (NN diabetes))
                  (, ,)
                  (CC and)
                  (NP (NN allergy) (CD -LSB-16,18,22) (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (JJ infectious) (NNS models)))
      (, ,)
      (NP (NN Treg))
      (ADVP (RB also))
      (VP (VBP influence)
        (NP (DT the) (NN effector) (JJ immune) (NN response))
        (, ,)
        (SBAR (IN as)
          (S
            (VP (VBZ is)
              (ADJP (JJ evident)
                (PP (IN in)
                  (NP (FW Leishmania) (JJ major) (NN infection) (CD -LSB-20))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (NP
        (ADJP (CC Both)
          (ADJP (JJ innate))
          (CC and)
          (ADJP (JJ adaptive)))
        (JJ immune) (NNS responses))
      (VP (VBP are)
        (ADJP (JJ subject)
          (PP (TO to)
            (NP (NN Treg) (NN control))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Triggering))
        (PP (IN of)
          (NP (JJ dendritic) (NNS cells)))
        (PP (IN by)
          (NP
            (NP (JJ Toll-like) (NN receptor) (NNS ligands))
            (VP (VBN expressed)
              (PP (IN by)
                (NP (JJ invading) (NNS pathogens)))))))
      (VP (VBZ leads)
        (PP (TO to)
          (NP
            (NP (DT the) (NN production))
            (PP (IN of)
              (NP
                (NP (JJ soluble) (NNS factors))
                (, ,)
                (PP (VBG including)
                  (NP (NN IL-6)))
                (, ,)
                (SBAR
                  (WHNP (WDT that))
                  (S
                    (VP (MD may)
                      (VP (VB render)
                        (NP
                          (NP (NN effector) (NNS cells))
                          (ADJP (JJ refractory)
                            (PP (TO to)
                              (NP (JJ regulatory) (NN activity) (CD -LSB-23)))))))
                    (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Moreover))
      (, ,)
      (NP (VBN activated) (JJ dendritic) (NNS cells))
      (VP (VBP produce)
        (NP (NN TGF-β))
        (, ,)
        (SBAR
          (WHNP (WDT which))
          (S
            (VP (MD may)
              (ADVP (RB further))
              (VP (VB influence)
                (NP
                  (NP (DT the) (NN development))
                  (PP (IN of)
                    (NP (NN Treg) (CD -LSB-24)))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (PP (IN By)
        (NP (JJ such) (JJ intersecting) (NNS pathways)))
      (, ,)
      (NP
        (NP (DT the)
          (ADJP
            (ADJP (JJ innate))
            (CC and)
            (ADJP (JJ regulatory)))
          (NNS arms))
        (PP (IN of)
          (NP (DT the) (JJ immune) (NN system))))
      (VP (VBP have)
        (NP (DT the) (NN capacity)
          (S
            (VP (TO to)
              (VP (VB exert)
                (NP (JJ sufficient) (NN control))
                (PP (IN over)
                  (NP (DT each) (JJ other))))
              (S
                (VP (TO to)
                  (VP (VB enable)
                    (S
                      (NP (NN effector) (NNS cells))
                      (VP (TO to)
                        (VP (VB mount)
                          (NP (JJ efficient) (JJ immune) (NNS responses))
                          (PP (IN with)
                            (NP (JJ minimal) (NN pathology))))))))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (JJ human)
          (ADJP
            (ADJP (JJ infectious))
            (, ,)
            (ADJP (JJ neoplastic))
            (, ,)
            (CC and)
            (ADJP (JJ autoimmune)))
          (NNS diseases)))
      (, ,)
      (NP (NN Treg) (NNS activities))
      (ADVP (RB often))
      (VP (VBP mirror)
        (NP
          (NP (DT those))
          (PP (IN in)
            (NP (JJ murine) (NNS systems))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Numbers))
        (PP (IN of)
          (NP (NN Treg))))
      (VP (VBP are)
        (ADVP (RB reportedly))
        (VP (VBN reduced)
          (PP (IN in)
            (NP (JJ human) (JJ autoimmune) (NNS diseases)
              (NP (CD -LSB-17,25) (-RRB- -RSB-))))
          (, ,)
          (SBAR (IN although)
            (S
              (NP
                (NP (PRP$ their) (NN significance))
                (PP (IN in)
                  (NP
                    (NP (DT the) (NN evolution))
                    (PP (IN of)
                      (NP (NNS immunopathogenesis))))))
              (VP (VBZ remains)
                (NP
                  (NP (DT an) (NN area))
                  (PP (IN of)
                    (NP (JJ continued) (NN exploration))))))))))
    (. .)))

(
  (S
    (S
      (S
        (ADVP (RB Moreover))
        (, ,)
        (NP (VBN increased) (JJ CD4+CD25+) (JJ regulatory) (NN T) (NNS cells))
        (VP (VBP have)
          (VP (VBN been)
            (VP (VBN reported)
              (PP (IN in)
                (NP (NN HIV-1) (NN immunodeficiency) (NN -LSB-26))))))
        (-RRB- -RSB-))
      (, ,)
      (CC and)
      (S
        (PP (IN in)
          (NP (NN lung) (NN cancer) (NNS patients)))
        (NP
          (NP (DT the) (VBN increased) (NNS numbers))
          (PP (IN of)
            (NP (JJ CD4+CD25+) (JJ regulatory) (NN T) (NNS cells))))
        (ADVP (RB directly))
        (VP (VBP inhibit)
          (NP (JJ autologous) (NN T) (NN cell) (NN proliferation) (CD -LSB-27) (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Thus))
      (, ,)
      (NP
        (NP (DT this)
          (ADJP
            (ADJP (JJ unique))
            (CC and)
            (ADJP (JJ persuasive)))
          (NN population))
        (PP (IN of)
          (NP (JJ regulatory) (NN T) (NNS cells))))
      (VP (VBZ has)
        (NP (DT a) (JJ crucial) (NN role))
        (PP (IN in)
          (NP
            (NP (DT the) (NN maintenance))
            (PP (IN of)
              (NP
                (NP (NN tolerance))
                (CC and)
                (NP (JJ immune) (NN homeostasis))))
            (PP (IN through)
              (NP (JJ immune) (NN suppression)))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Mechanism))
      (PP (IN of)
        (NP (NN Treg) (NN suppression))))))

(
  (S
    (S
      (NP (NN Treg))
      (VP (VBP are)
        (NP (CC both)
          (NP
            (ADJP (JJ anergic)))
          (, ,)
          (ADVP (IN at) (JJS least) (FW in) (FW vitro))
          (, ,)
          (CC and)
          (NP
            (ADJP (JJ immunosuppressive))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN absence))
        (PP (IN of)
          (NP (NN Treg))))
      (VP (VBZ results)
        (PP (IN in)
          (NP
            (NP
              (NP (DT the) (NN breakdown))
              (PP (IN of)
                (NP (NN tolerance))))
            (CC and)
            (NP
              (NP (DT the) (NN development))
              (PP (IN of)
                (NP (JJ autoimmune) (NNS diseases))))
            (NP (CD -LSB-28) (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (PRP$ Our) (NN understanding))
        (PP (IN of)
          (NP
            (NP (DT the) (JJ functional) (NN domain))
            (PP (IN of)
              (NP (DT these) (NNS cells))))))
      (VP (VBZ has)
        (ADVP (RB rapidly))
        (ADJP (JJ advanced))
        (PP (IN through)
          (NP (NN cell) (NN culture) (NNS experiments)))))
    (. .)))

(
  (S
    (S
      (ADVP (FW In) (FW vitro))
      (, ,)
      (NP
        (NP (DT the) (NN ability))
        (PP (IN of)
          (NP (NN CD4+CD25+) (NN Treg)))
        (S
          (VP (TO to)
            (VP (VB suppress)
              (NP
                (NP (NN responder) (NN T) (NN cell) (NN proliferation))
                (CC and)
                (NP (NN cytokine) (NN production)))))))
      (VP
        (VP (VBZ requires)
          (NP (PRP$ their) (NN activation)))
        (, ,)
        (VP (VBZ is)
          (ADJP (JJ dependent)
            (PP (IN on)
              (NP (NN cell) (NN contact)))))
        (, ,)
        (CC and)
        (VP (VBZ is)
          (NP (NN antigen) (JJ nonspecific) (NN -LSB-1,6,10))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (PP (IN After)
        (NP
          (NP (NNS years))
          (PP (IN of)
            (NP
              (NP (NN searching))
              (PP (IN for)
                (NP
                  (NP (DT the) (JJ elusive) (NN mediator) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-))
                  (PP (IN of)
                    (NP
                      (NP (NN suppression))
                      (ADJP (JJ consistent)
                        (PP (IN with)
                          (NP (DT the) (VBN accepted) (JJ cell-contact-dependent) (NN mechanism))))))))))))
      (, ,)
      (NP (JJ membrane-associated) (NN TGF-β))
      (VP (VBD was)
        (VP (VBN identified)
          (PP (IN as)
            (NP (DT a) (JJ pivotal) (NN perpetrator) (NN -LSB-6,7,14)))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT this) (NN regard)))
      (, ,)
      (NP (JJ latent) (NN TGF-β))
      (VP (VBD was)
        (ADVP (RB first))
        (VP (VBN reported)
          (S
            (VP (TO to)
              (VP (VB be)
                (ADJP (RB constitutively) (JJ present)
                  (PP (IN on)
                    (NP
                      (NP (DT the) (NN surface))
                      (PP (IN of)
                        (NP (NN Treg) (CD -LSB-6,7)))))))))))
      (-RRB- -RSB-))
    (: ;)
    (S
      (ADVP (RB subsequently))
      (, ,)
      (NP (JJ active) (NN TGF-β))
      (VP (VBD was)
        (VP (VBN identified)
          (NP (NN -LSB-6,8,14))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (ADJP (FW In) (FW vitro))
          (NN stimulation))
        (PP (IN with)
          (NP
            (NP (NN anti-CD3))
            (CC and)
            (NP
              (NP (JJ antigen-presenting) (NNS cells))
              (PRN (-LRB- -LRB-)
                (NP (NNS APCs))
                (-RRB- -RRB-))))))
      (VP (VBZ enhances)
        (NP
          (NP (JJ membrane-bound) (JJ active) (NN TGF-β))
          (, ,)
          (SBAR
            (WHNP (WDT which))
            (S
              (VP (VBZ is)
                (ADJP (JJ consistent)
                  (PP (IN with)
                    (NP (DT the) (NN requirement)
                      (SBAR (IN that)
                        (S
                          (NP (NN Treg) (NN activation))
                          (VP (VBZ promotes)
                            (NP (PRP$ their) (JJ suppressive) (JJ potential) (NN -LSB-6,13)))
                          (-RRB- -RSB-)
                          (PRN (-LRB- -LRB-)
                            (FRAG
                              (NP (NN W) (NNP Chen))
                              (, ,)
                              (NP (JJ unpublished) (NNS data)))
                            (-RRB- -RRB-)))))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Blockade))
      (PP (IN of)
        (NP (JJ cell-surface) (NNS TGF-β)))
      (PP
        (PP (IN with)
          (NP (NN neutralizing) (NNS antibodies)))
        (, ,)
        (PP (IN with)
          (NP (JJ soluble) (NN TGF-β) (NN receptor)))
        (, ,)
        (CC or)
        (PP (IN with)
          (NP (JJ recombinant) (JJ latency-associated) (NN peptide)))))
    (VP (VBZ disrupts)
      (NP
        (NP (DT the) (NN ability))
        (PP (IN of)
          (NP (DT these) (NNS cells)))
        (S
          (VP (TO to)
            (VP (VB block)
              (NP (NN responder) (NN T) (NN cell) (NN proliferation))))))
      (, ,)
      (S
        (VP (VBG confirming)
          (NP (NN TGF-β))
          (PP (IN as)
            (NP
              (NP (DT an) (NN instrument))
              (PP (IN of)
                (NP (NN suppression) (NN -LSB-6-8,12,13,15,29) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (NP (RB Still) (JJ missing))
      (VP (VBD was)
        (NP
          (NP (DT the) (VBG connecting) (NN link))
          (SBAR
            (WHPP (IN by)
              (WHNP (WDT which)))
            (S
              (NP (JJ membrane-bound) (NN TGF-β))
              (VP (MD could)
                (VP (VB interact)
                  (PP (IN with)
                    (NP (DT the) (NN CD4+CD25-) (NN responder) (NNS cells))))))))))
    (. .)))

(
  (S
    (ADVP (RB Recently))
    (, ,)
    (NP
      (NP (JJ TGF-β) (NN receptor) (NN type) (CD II))
      (PRN (-LRB- -LRB-)
        (NP (NN TβRII))
        (-RRB- -RRB-)))
    (VP (VBD was)
      (VP (VBN detected)
        (PP (IN at)
          (NP (JJ elevated) (NNS levels)))
        (PP (IN on)
          (NP (NN responder) (NN T) (NNS cells)))
        (SBAR (IN once)
          (S
            (NP (PRP they))
            (VP (VBD were)
              (VP (VBN activated)
                (PP (IN through)
                  (NP (PRP$ their) (NN TCR)))
                (, ,)
                (S
                  (ADVP (RB thereby))
                  (VP (VBG providing)
                    (NP
                      (NP (DT the) (JJ molecular) (NN bridge))
                      (SBAR
                        (WHPP (IN by)
                          (WHNP (WDT which)))
                        (S
                          (NP
                            (NP (NN TGF-β))
                            (PP (IN on)
                              (NP (DT the) (NN Treg))))
                          (VP (VBZ orchestrates)
                            (NP
                              (NP (NN suppression))
                              (PP (IN of)
                                (NP (DT the) (NN responder) (NNS cells)
                                  (NP (CD -LSB-6,8,12))))))
                          (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (NP
      (NP (JJ TGF-β) (NN signaling))
      (CC and)
      (NP (NN regulation)))))

(
  (S
    (S
      (NP (NN TGF-β))
      (VP (VBZ is)
        (NP
          (NP
            (NP (DT a) (JJ potent) (NN cytokine))
            (CC and)
            (NP (NN growth) (NN factor)))
          (SBAR
            (WHNP (WP$ whose) (JJ biological) (NN activity))
            (S
              (VP (VBZ is)
                (ADVP (RB primarily))
                (VP (VBN regulated)
                  (PRN
                    (QP (RB post-translationally) (CD -LSB-30))
                    (-RRB- -RSB-))
                  (, ,)
                  (SBAR (IN because)
                    (S
                      (NP (PRP it))
                      (VP (VBZ is)
                        (VP
                          (VP (VBN transcribed))
                          (CC and)
                          (VP (VBN translated)
                            (PP (IN as)
                              (NP
                                (NP (DT a) (JJ small) (JJ latent) (NN complex))
                                (VP (VBN composed)
                                  (PP
                                    (CONJP (RB not) (RB only))
                                    (PP (IN of)
                                      (NP (JJ active) (NN TGF-β)))
                                    (, ,)
                                    (CONJP (CC but)
                                      (RB also))
                                    (PP (IN of)
                                      (NP
                                        (NP
                                          (NP (DT a) (JJ latency-associated) (NN peptide))
                                          (PRN (-LRB- -LRB-)
                                            (NP (NN LAP))
                                            (-RRB- -RRB-)))
                                        (SBAR
                                          (WHPP (TO to)
                                            (WHNP (WDT which)))
                                          (S
                                            (NP (PRP it))
                                            (VP (VBZ is)
                                              (ADJP (RB noncovalently) (VBN bound))
                                              (SBAR (CC and)
                                                (WHNP (WDT which))
                                                (S
                                                  (VP (VBZ prevents)
                                                    (NP
                                                      (NP (PRP$ its) (NN interaction))
                                                      (PP (IN with)
                                                        (NP
                                                          (NP (PRP$ its) (JJ specific) (NNS receptors))
                                                          (PP (IN on)
                                                            (NP (DT the) (NN target) (NN cell) (NN surface))))))))))))))))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT This) (JJ small) (JJ latent) (NN complex))
      (VP (MD can)
        (VP (VB be)
          (VP (VBN associated)
            (PP (IN with)
              (NP (DT the) (JJ latent) (JJ TGF-β1-binding) (NN protein)))
            (, ,)
            (S
              (VP (VBG forming)
                (NP
                  (NP (DT a) (JJ large) (JJ latent) (NN complex))
                  (VP (VBN thought)
                    (S
                      (VP (TO to)
                        (VP (VB serve)
                          (PP (IN as)
                            (NP
                              (NP (DT a))
                              (VP (VBP tether)
                                (PP (IN for)
                                  (NP
                                    (NP (NN binding) (NNS proteins))
                                    (CC and)
                                    (NP (NN matrix) (NNS molecules))
                                    (NP (CD -LSB-31) (-RRB- -RSB-))))))))))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (DT this) (NN configuration)))
    (, ,)
    (NP (NN TGF-β))
    (VP
      (VP (VBZ is) (RB not)
        (ADJP (JJ active)))
      (CC but)
      (VP (VBZ requires)
        (NP
          (NP
            (NP (NN cleavage))
            (CC or)
            (NP (NN dissociation)))
          (PP (IN from)
            (NP (NN LAP)))
          (S
            (VP (TO to)
              (VP (VB enable)
                (NP
                  (NP (PRP$ its) (NN interaction))
                  (PP (IN with)
                    (NP (PRP$ its) (JJ cognate) (NN receptor) (NN complex))))))))
        (PRN (, ,)
          (NP
            (NP (NNP TβRII))
            (CC and)
            (NP (NNP TβRI) (CD -LSB-32)))
          (-RRB- -RSB-))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Activation))
        (PP (IN of)
          (NP (NN TGF-β))))
      (VP (MD can)
        (VP (VB occur)
          (PP (IN by)
            (NP
              (NP (DT any))
              (PP (IN of)
                (NP
                  (NP (DT a) (NN number))
                  (PP (IN of)
                    (NP
                      (NP (NNS mechanisms))
                      (PP (VBG including)
                        (NP
                          (NP (NN cleavage))
                          (PP
                            (PP (IN with)
                              (NP
                                (NP (NN plasmin) (CD -LSB-33) (-RRB- -RSB-))
                                (, ,)
                                (NP
                                  (NP (NN interaction))
                                  (PP (IN with)
                                    (NP (NN αvβ6) (CD -LSB-34)))
                                  (-RRB- -RSB-))
                                (, ,)))
                            (CC or)
                            (PP (IN through)
                              (NP
                                (NP (DT an) (JJ ill-defined) (NN interaction))
                                (PP (IN of)
                                  (NP (NN LAP)))
                                (PP (IN with)
                                  (NP
                                    (NP
                                      (NP (NN thrombospondin) (CD I))
                                      (PRN (-LRB- -LRB-)
                                        (NP (NN TSP-I))
                                        (-RRB- -RRB-)))
                                    (, ,)
                                    (NP
                                      (NP (DT a) (NN ligand))
                                      (PP (IN for)
                                        (NP (DT the) (NN CD36) (NN receptor) (CD -LSB-35)))
                                      (-RRB- -RSB-))))))))))))))))))
    (. .)))

(
  (S
    (S
      (VP (VBG Adding)
        (NP (NN credence))
        (PP (TO to)
          (NP
            (NP (DT a) (NN role))
            (PP (IN for)
              (NP (NN TSP-1)))))))
    (, ,)
    (NP (DT the) (JJ TSP-1-null) (NNS mice))
    (VP
      (VP (VBP exhibit)
        (NP (JJ persistent) (NN inflammation))
        (, ,)
        (ADVP (RB particularly))
        (PP (IN in)
          (NP (DT the)
            (NP
              (NP (NN pancreas))
              (CC and)
              (NP (NN lung))))))
      (, ,)
      (CC and)
      (VP (VBP display)
        (NP
          (NP (DT a) (NN phenotype))
          (PP (IN with)
            (NP
              (NP (NNS similarities))
              (PP
                (PP (TO to)
                  (NP (NN TGF-β-null) (NNS mice) (CD -LSB-36,37) (-RRB- -RSB-)))
                (, ,)
                (CONJP (IN although))
                (PP (TO to)
                  (NP (DT a) (JJR lesser) (NN extent)))))))
        (SBAR (IN because)
          (S
            (NP
              (NP (JJ alternative) (NNS mechanisms))
              (PP (IN of)
                (NP (NN TGF-β) (NN activation))))
            (VP (VB compensate))))))
    (. .)))

(
  (S
    (S
      (S
        (ADVP (RB Nonetheless))
        (, ,)
        (NP (NN TSP-1))
        (VP (VBZ is)
          (NP
            (NP (DT a) (JJ major) (NN activator))
            (PP (IN of)
              (NP (JJ TGF-β1)
                (ADJP (FW in) (FW vivo))
                (NN -LSB-36)))))
        (-RRB- -RSB-))
      (, ,)
      (CC and)
      (S
        (NP
          (NP (DT a) (NN TSP) (NN peptide))
          (SBAR
            (WHNP (WDT that))
            (S
              (VP (VBZ activates)
                (NP (NN TGF-β))))))
        (VP (VBZ reverses)
          (NP (DT the) (JJ TSP-1-null) (NN phenotype))
          (PP (IN by)
            (S
              (VP (VBG dampening)
                (NP (DT the) (NN tissue) (NN inflammation))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (DT a) (NN feedback) (NN loop)))
    (, ,)
    (S
      (S
        (NP (NN TGF-β))
        (VP (VBZ augments)
          (NP (NN TSP) (NN secretion))
          (PP (IN by)
            (NP
              (NP (JJ dendritic) (NNS cells))
              (CC and)
              (NP (NNS macrophages))))))
      (, ,)
      (CC and)
      (S
        (NP (JJ TGF-β-treated) (NNS APCs))
        (VP (VBP facilitate)
          (NP
            (NP
              (NP (DT the) (NN generation))
              (PP (IN of)
                (NP (JJ regulatory) (NN T) (NNS cells))))
            (NP (CD -LSB-38) (-RRB- -RSB-)))
          (, ,)
          (S
            (VP (VBG creating)
              (NP
                (NP (DT an) (NN environment))
                (ADJP (JJ favorable)
                  (PP (IN for)
                    (NP
                      (NP (DT the) (NN induction))
                      (PP (IN of)
                        (NP
                          (NP (NN suppression))
                          (CC and/or)
                          (NP (NN tolerance))))
                      (S
                        (VP (TO to)
                          (VP (VB ensure)
                            (NP
                              (NP (DT the) (NN blunting))
                              (PP (IN of)
                                (NP (DT any) (JJ inflammatory) (NN reaction))))))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Often))
      (NP (JJ seeming) (JJ paradoxical) (, ,) (VBN activated) (NN TGF-β))
      (VP (VBZ has)
        (NP
          (ADJP (CC both)
            (ADJP (JJ stimulatory))
            (CC and)
            (ADJP (JJ inhibitory)))
          (NNS influences))
        (PP (IN on)
          (NP (NN T) (NN cell) (NN function) (CD -LSB-6,8))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (NP (DT These)
        (ADJP (RB apparently) (JJ disparate))
        (NNS effects))
      (VP (VBP are)
        (ADJP (JJ dependent)
          (PP (IN on)
            (NP (NN context))))
        (, ,)
        (S
          (VP (VBG including)
            (NP
              (NP
                (NP (NN state))
                (PP (IN of)
                  (NP (NN differentiation))))
              (, ,)
              (NP
                (NP (NN presence))
                (PP (IN of)
                  (NP
                    (NP (JJ other) (NN growth) (NNS factors))
                    (CC or)
                    (NP
                      (NP (NNS cytokines))
                      (, ,)
                      (NP (NN matrix) (NNS molecules))
                      (, ,)
                      (NP (JJ additional) (JJ proximal) (NN cell) (NNS populations))
                      (, ,)))))
              (CC and)
              (NP (NN membrane) (NN receptor) (NNS levels)))))))
    (. .)))

(
  (S
    (S
      (PP (IN Beyond)
        (NP
          (NP (PRP$ its) (NN involvement))
          (PP (IN in)
            (NP (JJ contact-dependent) (NN suppression)))))
      (, ,)
      (NP (JJ soluble) (NN TGF-β))
      (VP (MD can)
        (ADVP (RB directly))
        (VP
          (VP (VB inhibit)
            (NP (NN T) (NN cell) (NN proliferation)))
          (, ,)
          (VP (VB suppress)
            (NP (NN macrophage) (NN activation)))
          (CC and)
          (VP (VB modulate)
            (NP
              (NP (JJ dendritic) (NN cell) (NN function))
              (PP (IN in)
                (NP
                  (NP (PRP$ its) (NN role))
                  (PP (IN as)
                    (NP (DT an) (JJ immunoregulatory) (NN cytokine))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Deletion))
        (PP (IN of)
          (NP (DT this) (NN cytokine))))
      (VP (VBZ is)
        (VP (VBN associated)
          (PP (IN with)
            (NP
              (NP (JJ lethal) (JJ immune) (NN dysregulation))
              (CC and)
              (NP (JJ multi-organ) (JJ inflammatory) (NN disease) (CD -LSB-39,40) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (S
          (VP (VBG mediating)
            (NP (PRP$ its) (JJ suppressive) (NNS effects)))))
      (, ,)
      (NP (NN TGF-β))
      (VP (VBZ signals)
        (PP (IN through)
          (NP
            (NP (DT the)
              (NP
                (NP (NN type) (CD I))
                (CC and)
                (NP (NN type) (CD II)))
              (JJ TGF-β) (JJ serine–threonine) (NN kinase) (NNS receptors))
            (, ,)
            (NP
              (NP (NN TβRI))
              (CC and)
              (NP (NN TβRII)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Interaction))
        (PP (IN of)
          (NP (DT the) (JJ TGF-β) (NN ligand)))
        (PP (IN with)
          (NP
            (NP (DT these) (NNS receptors))
            (PP (IN on)
              (NP (NN target) (NNS cells))))))
      (VP (VBZ engages)
        (NP
          (NP (DT a) (NN signaling) (NN cascade))
          (ADJP (JJ precipitated)
            (PP (IN by)
              (NP
                (NP (DT the) (NN phosphorylation))
                (PP (IN of)
                  (NP
                    (NP (JJ cytosolic) (NNS proteins))
                    (VP (VBN identified)
                      (PP (IN as)
                        (NP (NNP Smads) (CD -LSB-41,42) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (SBAR
      (WHADVP (WRB When))
      (S
        (NP (JJ CD4+CD25+) (NNS Treg))
        (VP (VBP are)
          (VP (VBN co-cultured)
            (PP (IN with)
              (NP (JJ TCR-activated) (NN CD4+CD25-) (NN responder) (NN T) (NNS cells)))))))
    (, ,)
    (NP (EX there))
    (VP (VBZ is)
      (NP
        (NP (DT a) (JJ rapid) (NN engagement))
        (PP (IN of)
          (NP (DT this) (JJ intracellular) (NN signaling) (NN pathway)))
        (SBAR
          (WHNP (WDT that))
          (S
            (VP (VBZ is)
              (ADJP (JJ consistent)
                (PP (IN with)
                  (NP (NN TGF-β))))
              (PP (IN as)
                (NP
                  (NP
                    (NP (DT the) (NN link))
                    (PP (IN between)
                      (NP (DT these) (CD two) (NNS cells))))
                  (CC and)
                  (NP
                    (NP (DT the) (JJ impending) (JJ functional) (NN inhibition))
                    (VP (VBN manifested)
                      (PP (IN in)
                        (NP (DT the) (NN responder) (NN cell) (NN population) (CD -LSB-6,12,15)))))))
              (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT this) (NN regard)))
      (, ,)
      (NP
        (NP (NN phosphorylation))
        (PP (IN of)
          (NP (NN Smads)))
        (, ,)
        (VP
          (ADVP (RB initially))
          (VBN detected)
          (PP
            (PP (IN with)
              (NP
                (NP (NNS antibodies))
                (SBAR
                  (WHNP (WDT that))
                  (S
                    (VP (VBP recognize)
                      (NP (CC both)
                        (NP (NN Smad2))
                        (CC and)
                        (NP
                          (NP (NN Smad3) (CD -LSB-6) (-RRB- -RSB-))
                          (PRN (-LRB- -LRB-)
                            (FRAG
                              (NP (NN W) (NNP Chen))
                              (, ,)
                              (NP (JJ unpublished) (NNS data)))
                            (-RRB- -RRB-)))))))))
            (, ,)
            (CC and)
            (ADVP (RBR more) (RB recently))
            (PP (IN with)
              (NP
                (NP (JJ Smad2-specific) (NNS antibodies))
                (NP (CD -LSB-15) (-RRB- -RSB-))))))
        (, ,))
      (VP (VBD occurred)
        (PP (IN within)
          (NP
            (NP (NNS minutes))
            (PP (IN after)
              (NP
                (NP (NN exposure))
                (PP (IN of)
                  (NP (NN responder) (NN T) (NNS cells)))
                (PP (TO to)
                  (NP (NN Treg)))))))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (NN Smad2))
          (CC and)
          (NP (NN Smad3)))
        (VP (VBP serve)
          (PP (IN as)
            (NP (JJ receptor-activated) (NN Smad) (NN signaling) (NNS intermediates)))))
      (, ,) (IN whereas)
      (S
        (NP (NN Smad4))
        (VP (VBZ is)
          (NP
            (NP (DT a) (JJ common) (NN Smad))
            (SBAR (IN that)
              (S
                (NP
                  (NP (NNS complexes))
                  (PP (IN with)
                    (NP (NN Smad2/3))))
                (VP (TO to)
                  (VP (VB enable)
                    (NP
                      (NP (NN translocation))
                      (PP (TO to)
                        (NP (DT the) (NN nucleus))))))))))))
    (. .)))

(
  (S
    (PP (IN Once)
      (PP (IN within)
        (NP (DT the) (NN nucleus))))
    (, ,)
    (NP (DT the) (NN Smad) (NN complex))
    (VP (MD may)
      (VP (VB interact)
        (PP
          (PP (IN with)
            (NP (JJ specific) (NN DNA) (NNS sequences)))
          (CC and)
          (PP (IN with)
            (NP (JJ multiple) (JJ specific) (NN transcription) (NNS factors))))
        (, ,)
        (S
          (PP (IN in)
            (NP
              (NP (NN addition))
              (PP (TO to)
                (NP (JJ transcriptional)
                  (NP (NNS coactivators))
                  (CC and/or)
                  (NP (NNS co-repressors))))))
          (, ,)
          (VP (VBG culminating)
            (PP (IN in)
              (NP
                (NP
                  (NP (DT the) (NN transcription))
                  (PP (IN of)
                    (NP (NN target) (NNS genes))))
                (CC and)
                (NP
                  (NP (DT the) (NN transduction))
                  (PP (IN of)
                    (NP
                      (NP (DT a) (NN variety))
                      (PP (IN of)
                        (NP
                          (NP (NNS signals))
                          (ADJP (JJ dependent)
                            (PP (IN on)
                              (NP (DT the) (NN target) (NN cell) (NN -LSB-41))))))))))))
          (-RRB- -RSB-))))
    (. .)))

(
  (S
    (S
      (NP (NN Smad2/3))
      (VP (VBP are)
        (VP (VBN anchored)
          (PP (TO to)
            (NP (DT the) (NN plasma) (NN membrane)))
          (PP (IN through)
            (NP
              (NP (DT the) (NN Smad) (NN anchor))
              (PP (IN for)
                (NP (NN receptor) (NN activation))))))
        (PRN (-LRB- -LRB-)
          (NP (NN SARA))
          (-RRB- -RRB-))
        (, ,)
        (SBAR
          (WHNP (WDT which))
          (S
            (ADVP (RB probably))
            (VP (VBZ increases)
              (NP
                (NP (DT the) (NN efficiency))
                (PP (IN of)
                  (NP (NN activation))))
              (PP (IN by)
                (NP (DT the) (JJ TGF-β-receptor) (NNS complexes)
                  (NP (CD -LSB-43)))))
            (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Smad2))
        (, ,)
        (CONJP (RB rather) (IN than))
        (NP (NN Smad3))
        (, ,))
      (VP (MD may)
        (VP (VB be)
          (NP (DT the) (JJ critical) (NN connector))
          (PP (IN in)
            (NP
              (NP (DT the) (JJ intracellular) (NN signaling) (NN pathway))
              (VP (VBN engaged)
                (PP (IN in)
                  (NP (DT the) (NN responder) (NNS cells)))
                (PP (IN by)
                  (NP (NN Treg) (NN surface-bound) (NN TGF-β))))))
          (, ,)
          (SBAR (IN because)
            (S
              (NP
                (NP (NNS mice))
                (ADJP (JJ deficient)
                  (PP (IN in)
                    (NP (NN Smad3)))))
              (VP (VBP respond)
                (PP
                  (PP (TO to)
                    (NP (NN Treg) (NN suppression)))
                  (CONJP (CC and)
                    (RB also))
                  (PP (TO to)
                    (NP (JJ exogenous) (JJ TGF-β) (NN -LSB-6)))))
              (-RRB- -RSB-)
              (PRN (-LRB- -LRB-)
                (FRAG
                  (NP (NN W) (NNP Chen))
                  (, ,)
                  (NP (JJ unpublished) (NNS data)))
                (-RRB- -RRB-)))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (NN addition))
          (PP (TO to)
            (NP
              (NP (DT that))
              (VP (VBN mediated)
                (PP (IN by)
                  (NP (NN Smad2))))))))
      (, ,)
      (NP (JJ TGF-β) (NN signaling))
      (VP (VBZ is)
        (VP (VBN regulated)
          (PP (IN by)
            (NP (JJ complex) (NNS mechanisms)))
          (PP (IN in)
            (NP (DT the)
              (NP
                (NP (NN cytoplasm))
                (CC and)
                (NP (NN nucleus))))))))
    (. .)))

(
  (S
    (S
      (PP (IN Beyond)
        (S
          (VP (VBG engaging)
            (NP (NN Smad) (NN activity)))))
      (, ,)
      (NP (NN TGF-β))
      (VP (VBZ triggers)
        (NP
          (NP (DT the)
            (NP
              (NP (JJ extracellular) (JJ signal-related) (NN kinase))
              (CC and)
              (NP (NN p38) (JJ mitogen-activated) (NN kinase)))
            (NNS pathways))
          (CD -LSB-44) (-RRB- -RSB-)
          (S
            (VP (TO to)
              (VP (VB link)
                (NP
                  (NP (JJ additional) (NN signaling) (NNS cascades))
                  (VP (VBN involved)
                    (PP (IN in)
                      (S
                        (VP (VBG modulating)
                          (NP (NN cell) (NN function)))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Perturbations))
        (PP (IN in)
          (NP (DT this) (JJ immunoregulatory) (NN circuit))))
      (VP (MD can)
        (VP (VB occur)
          (PP (IN through)
            (NP
              (NP (NN dysregulation))
              (PP (IN of)
                (NP
                  (NP (DT the) (JJ inhibitory) (NN Smad))
                  (, ,)
                  (NP (NN Smad7))
                  (, ,)
                  (SBAR
                    (WHNP (WDT which))
                    (S
                      (ADVP (RB typically))
                      (VP (VBZ represses)
                        (NP (NN TGF-β) (NN signaling))
                        (PP
                          (PP (IN by)
                            (S
                              (VP (VBG interacting)
                                (PP (IN with)
                                  (NP (VBN activated) (NN TGF-β) (NNS receptors)))
                                (S
                                  (VP (TO to)
                                    (VP (VB prevent)
                                      (NP
                                        (NP (DT the) (NN activation))
                                        (PP (IN of)
                                          (NP (NN Smad2/3))))))))))
                          (CC and/or)
                          (PP (IN by)
                            (S
                              (VP (VBG interfering)
                                (PP (IN with)
                                  (NP
                                    (NP (NN complex) (NN formation))
                                    (PP (IN between)
                                      (NP
                                        (NP (NN Smad2/3))
                                        (CC and)
                                        (NP (NN Smad4) (CD -LSB-45) (-RRB- -RSB-))))))))))))))))))))
    (. .)))

(
  (S
    (S
      (VP (VBG Facilitating)
        (S
          (NP (DT the) (JJ inhibitory) (NN Smad) (NNS signals))
          (VP (VBP are)
            (NP
              (NP
                (NP
                  (NP (DT the) (NN Smad) (NN ubiquitin) (JJ regulatory) (NNS factors))
                  (PRN (-LRB- -LRB-)
                    (NP (NN Smurfs))
                    (-RRB- -RRB-)))
                (, ,)
                (NP (NN E3) (NN ubiquitin) (NNS ligases))
                (, ,))
              (ADJP (JJ capable)
                (PP (IN of)
                  (S
                    (VP (VBG inducing)
                      (NP
                        (NP
                          (NP (NN polyubiquitination))
                          (CC and)
                          (NP (NN degradation)))
                        (PP (IN of)
                          (NP (NNP TβRI) (CD -LSB-46,47) (-RRB- -RSB-)))))))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Smad7))
      (VP (VBZ is)
        (ADJP (JJ inducible)
          (PP (IN by)
            (NP (NN TGF-β) (PRP itself)))
          (PP
            (PP (IN as)
              (NP
                (NP (NN part))
                (PP (IN of)
                  (NP (DT a) (NN feedback) (NN loop)))))
            (, ,)
            (CONJP (RB as) (RB well) (IN as))
            (PP (IN by)
              (NP
                (NP (DT the)
                  (ADJP
                    (ADJP (JJ IFN-γ))
                    (CC and)
                    (ADJP (JJ NF-κB)))
                  (NNS pathways))
                (CD -LSB-41) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (ADVP (RB Moreover))
    (, ,)
    (NP
      (NP (DT the) (JJ transcriptional) (NNS co-repressors))
      (NP
        (NP (NN c-Ski))
        (CC and)
        (NP (NN SnoN))))
    (, ,)
    (PP (IN by)
      (NP
        (NP (NNS means))
        (PP (IN of)
          (NP
            (NP (PRP$ their) (NNS interactions))
            (PP (IN with)
              (NP (NN Smad2/3/4)))))))
    (, ,)
    (VP
      (VP (VBP repress)
        (NP (JJ TGF-β-induced) (NN transcription)))
      (CC and)
      (VP (VBP are)
        (VP (VBN upregulated)
          (PP (IN by)
            (NP (NN TGF-β)))
          (PP (IN as)
            (NP
              (NP (DT another) (JJ negative) (NN feedback) (NN loop))
              (S
                (VP (TO to)
                  (VP (VB maintain)
                    (NP
                      (NP (NN control))
                      (PP (IN of)
                        (NP (DT this)
                          (ADJP (RB incredibly) (JJ powerful))
                          (NN molecule) (CD -LSB-41) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Dissection))
        (PP (IN of)
          (NP (DT these) (NNS circuits))))
      (VP (MD will)
        (ADVP (RB probably))
        (VP (VBP reveal)
          (NP
            (NP (NNS pathways))
            (SBAR
              (WHPP (IN by)
                (WHNP (WDT which)))
              (S
                (NP (NN suppression))
                (VP (MD can)
                  (VP (VB be)
                    (VP (VBN manipulated)
                      (S
                        (VP (TO to)
                          (VP (VBP orchestrate)
                            (NP
                              (NP (NNS changes))
                              (PP (IN in)
                                (NP (JJ aberrant) (NN immunity))))))))))))))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Although)
        (S
          (NP
            (NP (DT the) (NN preponderance))
            (PP (IN of)
              (NP (NN evidence))))
          (VP (VBZ supports)
            (NP
              (NP (DT a) (JJ major) (NN role))
              (PP (IN for)
                (NP (NN TGF-β)))
              (PP (IN in)
                (NP
                  (NP (DT the) (NN mediation))
                  (PP (IN of)
                    (NP (NN Treg) (JJ suppressive) (NN activity)))))))))
      (, ,)
      (NP (EX there))
      (VP (VBP are)
        (ADJP (JJ likely)
          (S
            (VP (TO to)
              (VP (VB be)
                (NP
                  (NP
                    (NP (JJ additional) (NNS factors))
                    (CC and/or)
                    (NP (NNS cofactors)))
                  (SBAR
                    (SBAR
                      (WHNP (WDT that))
                      (S
                        (ADVP (RB secondarily))
                        (VP (VBP contribute)
                          (PP (TO to)
                            (NP (PRP$ their) (NN function))))))
                    (CC and)
                    (SBAR
                      (WHNP (WDT that))
                      (S
                        (VP (MD may)
                          (VP (VB become)
                            (ADJP (JJ prevalent)
                              (PP (IN in)
                                (NP
                                  (NP (DT the) (NN absence))
                                  (PP (IN of)
                                    (NP (NN TGF-β))))))))))
                    (CC and/or)
                    (SBAR (IN if)
                      (S
                        (NP (NN TGF-β))
                        (VP (VBZ is)
                          (VP (VBN dysregulated)))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The)
          (NP (NN identification))
          (CC and)
          (NP (NN intersection))
          (NP (NNS points)))
        (PP (IN of)
          (NP (JJ such) (NNS pathways))))
      (VP (VBP await)
        (NP (JJ further) (NN study))))
    (. .)))

(
  (S
    (SINV
      (PP (IN Among)
        (NP
          (NP (DT the) (NNS factors))
          (SBAR
            (WHNP (WDT that))
            (S
              (VP (VBP contribute)
                (PP (TO to)
                  (NP
                    (NP (DT the) (NN regulation))
                    (PP (IN of)
                      (NP (NN TGF-β)))
                    (PP (IN in)
                      (NP (NN CD4+CD25+) (NNS Treg))))))))))
      (VP (VBP are)
        (NP
          (NP
            (NP (NN CD28))
            (, ,)
            (NP (JJ cytotoxic) (NN T) (NN lymphocyte) (CD antigen-4))
            (, ,)
            (NP (JJ glucocorticoid-induced) (NN TNF) (NN receptor))
            (CC and)
            (NP (JJ forkhead/winged) (NN helix)
              (CC or)
              (NN forkhead) (NN box) (NN P3)))
          (VP (VBN encoded)
            (PP (IN by)
              (NP (NN Foxp3) (CD -LSB-48-51) (-RRB- -RSB-))))))
      (. .))))

(
  (S
    (NP
      (NP (NN Generation))
      (PP (IN of)
        (NP (NN Treg))))))

(
  (S
    (SBAR (IN Although)
      (S
        (NP (NN Treg))
        (VP (VBD were)
          (ADVP (RB originally))
          (VP (VBN considered)
            (S
              (VP (TO to)
                (VP (VB derive)
                  (PP
                    (ADVP (RB only))
                    (IN from)
                    (NP (JJ thymic) (NNS precursors)))
                  (NP (NN -LSB-1))
                  (-RRB- -RSB-) (, ,)
                  (S
                    (S
                      (VP (TO to)
                        (VP (VB be)
                          (VP (VBN exported)
                            (PP (TO to)
                              (NP (DT the) (NN periphery)))))))
                    (, ,)
                    (CC and)
                    (S
                      (VP (TO to)
                        (VP (VB represent)
                          (NP
                            (NP
                              (NP
                                (QP (JJR less) (IN than) (CD 10))
                                (NN %))
                              (PP (IN of)
                                (NP (JJ CD4+) (NN T) (NNS cells))))
                            (NP (CD -LSB-52) (-RRB- -RSB-)))
                          (, ,)
                          (S
                            (ADVP (RB thereby))
                            (VP (VBG limiting)
                              (NP
                                (NP (PRP$ their) (NN potential))
                                (PP (IN for)
                                  (NP (NN manipulation)))
                                (PP (IN for)
                                  (NP (JJ therapeutic) (NNS considerations)))))))))))))))))
    (, ,)
    (NP (JJ important) (JJ new) (NN evidence))
    (VP (VBZ documents)
      (SBAR (IN that)
        (S
          (NP (NN Treg))
          (VP (MD can)
            (VP (VB be)
              (VP
                (VP (VBN expanded))
                (CC and/or)
                (VP (VBN induced)
                  (ADVP (FW de) (FW novo))
                  (PP (IN from)
                    (NP (NN CD4+CD25-) (NN precursor) (NN T) (NNS cells))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (WRB How))
      (, ,)
      (SBAR (WRB where) (, ,)
        (CC and)
        (SBAR (IN if)
          (S
            (NP
              (NP (DT the)
                (NP
                  (NP (NN size))
                  (CC and)
                  (NP (NN function))))
              (PP (IN of)
                (NP (DT this) (NN population))))
            (VP (MD can)
              (VP (VB be)
                (ADVP (RB intentionally))
                (VP (VBN controlled)))))))
      (VP (VBZ is)
        (PP (IN of)
          (NP (DT the) (JJ utmost) (NN importance)))))
    (. .)))

(
  (S
    (S
      (S
        (NP
          (NP (DT The) (JJ thymic) (NN derivation))
          (PP (IN of)
            (NP (NN Treg))))
        (VP (VBZ is)
          (ADVP (RB genetically))
          (ADJP
            (CONJP (RB as) (RB well) (IN as))
            (ADJP (RB developmentally) (VBN regulated))
            (, ,))))
      (CC but)
      (S
        (NP (PRP it))
        (VP (VBZ seems)
          (S
            (VP (TO to)
              (VP (VB be)
                (ADJP
                  (ADJP (JJ constitutive))
                  (CC and)
                  (ADJP (RB relatively) (JJ stable)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Recruitment))
        (PP (TO to)
          (NP
            (NP (DT a) (NN site))
            (PP (IN of)
              (NP (JJ autoimmune) (NN reactivity))))))
      (VP (MD may)
        (VP (VB increase)
          (NP (PRP$ their) (NNS numbers))
          (ADVP (RB locally)))
        (, ,)
        (CC but)
        (PP (IN in)
          (NP (DT a) (JJ limited) (NN fashion)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN ability))
        (PP (TO to)
          (NP
            (NP (NN coerce) (NN expansion))
            (PP (IN of)
              (NP (JJ functional) (NN Treg))))))
      (VP (VBZ opens)
        (PP (IN up)
          (NP
            (NP (NNS possibilities))
            (PP (IN for)
              (NP
                (NP (DT the) (NN manipulation))
                (PP (IN of)
                  (NP
                    (NP (NN inflammation))
                    (CC and)
                    (NP (NN immunity))))))))))
    (. .)))

(
  (S
    (S
      (NP (JJ CD4+CD25+) (NNS Treg))
      (VP (VBP undergo)
        (NP
          (NP (NN proliferation))
          (PP (IN with)
            (NP (NN TCR) (NN stimulation))))
        (PP (IN in)
          (NP
            (NP (DT the) (NN presence))
            (PP (IN of)
              (NP
                (NP
                  (NP (JJ high) (NNS doses))
                  (PP (IN of)
                    (NP (JJ exogenous) (NN IL-2))))
                (PRN (-LRB- -LRB-)
                  (NP
                    (QP (JJR more) (IN than) (CD 100))
                    (NN U/ml))
                  (-RRB- -RRB-)
                  (NP
                    (ADJP (FW in) (FW vitro))
                    (NN -LSB-10))
                  (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Importantly))
      (, ,)
      (NP (DT these) (VBN expanded) (JJ CD4+CD25+) (JJ regulatory) (NN T) (NNS cells))
      (VP (VBP preserve)
        (NP
          (NP (PRP$ their) (JJ anergic) (NNS features))
          (CC and)
          (NP (JJ immunosuppressive) (NN ability)))
        (SBAR (IN once)
          (S
            (NP (NN IL-2))
            (VP (VBZ is)
              (VP (VBN removed)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT This) (JJ unique) (NN aspect))
        (PP (IN of)
          (NP (NN CD4+CD25+) (NNS Treg))))
      (VP (VBZ has)
        (NP (JJ definite) (JJ potential) (NN application))
        (PP (IN in)
          (S
            (VP (VBG designing)
              (NP
                (NP
                  (NP (JJ future) (JJ clinical) (NN therapy))
                  (PP (IN for)
                    (NP (JJ autoimmune) (NNS diseases))))
                (, ,)
                (NP (NN inflammation))
                (CC and)
                (NP (NN transplantation))))))))
    (. .)))

(
  (S
    (ADVP (RB Nonetheless))
    (, ,)
    (NP
      (NP (DT the) (NN insufficiency))
      (PP (IN of)
        (NP
          (ADJP (RB naturally) (VBN derived))
          (NN CD4+CD25+) (NN Treg)))
      (PP (IN in)
        (NP
          (NP (NN autoimmunity))
          (CC and)
          (NP (JJ other) (JJ immune) (NNS diseases)))))
    (VP (VBZ has)
      (VP (VBN driven)
        (NP
          (NP (DT the) (NN search))
          (PP (IN for)
            (NP (NNS approaches))))
        (S
          (VP (TO to)
            (VP (VBP convert)
              (NP (JJ normal) (JJ naive) (NN CD4+CD25-T) (NNS cells))
              (PP (IN into)
                (NP (JJ CD4+CD25+) (JJ regulatory) (NN T) (NNS cells))))))))
    (. .)))

(
  (S
    (NP
      (NP (DT The) (NN generation))
      (PP (IN of)
        (NP
          (ADJP (RB functionally) (JJ uncompromised))
          (NN CD4+CD25+) (NNS Treg))))
    (VP (VBZ involves)
      (NP
        (NP (DT the) (JJ unique) (NN induction))
        (PP (IN of)
          (NP (JJ forkhead/winged) (NN helix) (NN transcription) (NN factor) (NN Foxp3) (-LRB- -LRB-) (NN Scurfin) (-RRB- -RRB-)))
        (PP (IN in)
          (NP (JJ Foxp3-negative) (NN CD4+CD25-) (NNS precursors)))))
    (. .)))

(
  (S
    (S
      (S
        (NP (NN Foxp3))
        (VP (VBZ is)
          (VP
            (ADVP (RB highly))
            (VBN conserved))))
      (, ,)
      (CC and)
      (S
        (PP (IN in)
          (NP (CC both)
            (NP (NNS mice))
            (CC and)
            (NP (NNS humans))))
        (NP
          (ADJP (RB genetically) (JJ defective))
          (NN Foxp3))
        (VP (VBZ is)
          (VP (VBN associated)
            (PP (IN with)
              (NP
                (ADJP
                  (ADJP (JJ autoimmune))
                  (CC and)
                  (ADJP (JJ inflammatory)))
                (NN disease) (CD -LSB-48,53-57) (-RRB- -RSB-)))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (NN Foxp3) (JJ null) (NNS mice)))
      (, ,)
      (NP
        (NP (DT the) (NN deficiency))
        (PP (IN of)
          (NP (NN CD4+CD25+) (NN Treg))))
      (VP (VBZ results)
        (PP (IN in)
          (NP (DT a) (JJ lethal) (JJ autoimmune) (NN syndrome) (CD -LSB-53,55,57))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (ADVP (FW In) (FW vitro))
    (, ,)
    (NP
      (NP (NN gene) (NN transfer))
      (PP (IN of)
        (NP (NN Foxp3))))
    (VP (VBZ converts)
      (NP (JJ naive) (NN CD4+CD25-) (NN T) (NNS cells))
      (PP (IN into)
        (NP
          (NP
            (ADJP
              (ADJP (JJ phenotypic))
              (CC and)
              (ADJP (JJ functional)))
            (NN Treg) (CD -LSB-48,53,55,56) (-RRB- -RSB-))
          (, ,)
          (SBAR
            (WHNP (WDT which))
            (S
              (VP (VBZ is)
                (ADJP (JJ consistent)
                  (PP (IN with)
                    (NP (DT the) (NN ability)
                      (S
                        (VP (TO to)
                          (VP (VB rescue)
                            (NP
                              (NP (JJ Foxp3-null) (NNS mice))
                              (PP (IN with)
                                (NP
                                  (NP (JJ adoptive) (NN transfer))
                                  (PP (IN of)
                                    (NP (NN Treg) (NN -LSB-55) (-RRB- -RSB-))))))))))))))))))
    (. .)))

(
  (S
    (S
      (NP (DT These) (NNS data))
      (VP (VBP support)
        (NP
          (NP (DT the)
            (ADJP
              (ADJP (JJ pivotal))
              (CC and)
              (ADJP (JJ nonredundant)))
            (NN role))
          (PP (IN of)
            (NP (DT this) (NN transcription) (NN factor)))
          (PP (IN in)
            (NP
              (NP (NN Treg) (NN development))
              (CC and)
              (NP (NN function)))))))
    (. .)))

(
  (S
    (ADVP (RB Conversely))
    (, ,)
    (NP
      (NP (DT the) (NN overexpression))
      (PP (IN of)
        (NP (NN Foxp3)))
      (PP (IN in)
        (NP (DT a) (JJ transgenic) (NN mouse) (NN model))))
    (VP (VBZ results)
      (S
        (PP (IN in)
          (NP
            (NP (VBN enhanced) (NNS numbers))
            (PP (IN of)
              (NP
                (NP (NN CD4+CD25+) (NN Treg))
                (CC and)
                (, ,)
                (ADVP (RB furthermore))
                (, ,)
                (NP (JJ Foxp3-expressing) (NN CD4+CD25-))))))
        (, ,)
        (NP
          (NP
            (ADJP
              (CONJP (RB as) (RB well) (IN as))
              (ADJP (JJ CD4-CD8+))
              (, ,))
            (NN T) (NNS cells))
          (PP (IN in)
            (NP (DT these) (JJ transgenic) (NNS mice))))
        (ADVP (RB constitutively))
        (VP (VBP exhibit)
          (NP
            (NP (JJ suppressive) (NNS functions))
            (CD -LSB-57) (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (PP (IN Despite)
      (NP
        (NP (DT the) (NN success))
        (PP (IN of)
          (NP
            (NP (DT the) (JJ artificial) (NN gene) (NN transfer))
            (PP (IN of)
              (NP (NN Foxp3)))
            (PP (IN into)
              (NP (NN CD4+CD25-) (JJ naive) (NN T) (NNS cells)))
            (PP (TO to)
              (NP (NN coerce) (PRP them)))))
        (PP (IN into)
          (NP (DT a) (JJ CD4+CD25+) (JJ regulatory) (NN T) (NN cell) (NN phenotype)))))
    (, ,)
    (NP
      (NP (DT the) (NN existence))
      (PP (IN of)
        (NP
          (NP (DT a) (JJ physiologic) (NN inducer))
          (PP (IN of)
            (NP (NN Foxp3))))))
    (VP (VBD was)
      (ADJP (JJ unknown)))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (JJ recent) (NN elucidation))
        (PP (IN of)
          (NP
            (NP (DT a) (NN signaling) (NN pathway))
            (VP (VBG leading)
              (PP (TO to)
                (NP
                  (NP (DT the) (NN conversion))
                  (PP (IN of)
                    (NP (NN CD4+CD25-) (NNS precursors)))
                  (PP (IN into)
                    (NP (NN Treg)))))))))
      (VP (VBD revealed)
        (NP
          (NP (DT a) (JJ pivotal) (NN role))
          (PP (IN for)
            (NP (JJ TGF-β) (NN -LSB-8,12,14) (-RRB- -RSB-))))))
    (. .)))

(
  (S
    (ADVP (RB Moreover))
    (, ,)
    (NP
      (NP (DT the) (JJ genetic) (NN deletion))
      (PP (IN of)
        (NP (NN Foxp3))))
    (VP (VBZ results)
      (PP (IN in)
        (NP
          (NP (DT an) (JJ overlapping) (NN phenotype))
          (PP (IN with)
            (NP (DT the) (JJ TGF-β1-null) (NNS mice)))))
      (NP (CD -LSB-40))
      (-RRB- -RSB-) (, ,)
      (S
        (VP (VBG implicating)
          (NP
            (NP (DT a)
              (ADJP
                (ADJP (NN connection))
                (CC and/or)
                (ADJP (JJ shared)))
              (NN mechanism))
            (PP (IN of)
              (NP (NN action)))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (NN induction))
        (PP (IN of)
          (NP (NN gene) (NN expression)))
        (PP (IN of)
          (NP
            (NP (NN Foxp3))
            (, ,)
            (NP
              (NP (DT a) (NN transcription) (NN factor))
              (ADJP (JJ unique)
                (PP (TO to)
                  (NP (NN Treg) (CD -LSB-48,53-57)))))))
        (-RRB- -RSB-))
      (VP (VBZ is) (, ,)
        (PP (IN in)
          (NP (NN fact)))
        (, ,)
        (NP
          (ADJP (NN TGF-β) (JJ dependent))
          (CD -LSB-12) (-RRB- -RSB-))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP (NN TGF-β))
      (VP
        (VP (VBZ cannot)
          (VP (VB act)
            (ADVP (RB independently))
            (PP (IN on)
              (S
                (NP (NN precursor) (NNS cells))
                (VP (TO to)
                  (VP (VB generate)
                    (NP (NN Treg))))))))
        (CC but)
        (VP (VBZ requires)
          (NP
            (NP (NN co-stimulation))
            (PP (IN through)
              (NP
                (NP (NN TCR))
                (CC and)
                (NP (NN IL-2R) (NN -LSB-12,58)))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (NP
      (NP (JJ Naive) (JJ splenic) (NN CD4+CD25-) (NN T) (NNS cells))
      (VP (VBN cultured)
        (PP (IN for)
          (NP
            (QP (CD 7) (TO to) (CD 9))
            (NNS days)))
        (PP (IN with)
          (NP
            (NP (NN TCR) (NN stimulation))
            (CC and)
            (NP (NN TGF-β))))
        (PP (IN in)
          (NP
            (NP (DT the) (NN presence))
            (PP (IN of)
              (NP (NNS APCs)))))))
    (VP (VB emerge)
      (PP (IN as)
        (NP (NN CD4+CD25+) (NN Treg)))
      (PP (IN with)
        (NP (DT the) (NN ability)
          (S
            (VP (TO to)
              (VP (VB suppress)
                (NP (JJ CD4+) (NN responder) (NN T) (NN cell) (NN proliferation))))))))
    (. .)))

(
  (S
    (S
      (NP (DT A) (JJ similar) (NN conversion) (NN pattern))
      (VP (VBZ occurs)
        (PP (IN in)
          (NP (NN TCR) (JJ transgenic) (NNS mice)))
        (SBAR (IN if)
          (S
            (NP (DT the) (NN CD4+CD25-) (JJ naive) (NN T) (NNS cells))
            (VP (VBP are)
              (VP (VBN stimulated)
                (PP (IN with)
                  (NP
                    (NP (JJ specific) (NN antigen))
                    (CC and)
                    (NP
                      (NP (NNS APCs))
                      (PP (IN with)
                        (NP
                          (ADJP (RB TGF-β) (VBN added))
                          (NN -LSB-12) (-RRB- -RSB-))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT This) (NN engagement))
        (PP (IN of)
          (NP (DT the)
            (NP (NN TCR))
            (CC and)
            (NP
              (NP (NN co-stimulator) (NNS molecules))
              (PRN (-LRB- -LRB-)
                (ADJP (JJ such)
                  (PP (IN as)
                    (NP (NN CD28) (-RRB- -RRB-) (CD -LSB-49,50,59,60))))
                (-RRB- -RSB-)))))
        (PP (IN in)
          (NP
            (NP (NN concert))
            (PP (IN with)
              (NP (NN TβRII) (NN ligation))))))
      (VP (VBZ triggers)
        (NP
          (NP (NN signaling) (NNS pathways))
          (SBAR
            (WHNP (WDT that))
            (S
              (VP (VBP culminate)
                (PP (IN in)
                  (NP
                    (NP (NN Foxp3) (NN transcription))
                    (, ,)
                    (SBAR
                      (WHNP (WDT which))
                      (S
                        (VP (VBZ is)
                          (ADJP (JJ essential)
                            (PP (TO to)
                              (NP
                                (NP (NN generation))
                                (PP (IN of)
                                  (NP (NN Treg)))))))))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (DT this) (NN fashion)))
    (, ,)
    (NP (NN TGF-β))
    (VP
      (VP (VBZ is) (RB not)
        (ADVP (RB only))
        (VP (VBN expressed)
          (PP (IN by)
            (NP (NN Treg)))))
      (CC but)
      (ADVP (RB also))
      (VP (VBZ programs)
        (NP (PRP$ their)
          (NP (NN development))
          (CC and)
          (NP (NN function)))))
    (. .)))

(
  (S
    (NP (JJ TGF-β-converted) (NNS Treg))
    (VP (VBP control)
      (NP (JJ immune) (NNS responses))
      (ADVP (FW in) (FW vivo)))))

(
  (S
    (S
      (PP (IN On) (DT the) (NN basis) (IN of)
        (NP
          (NP (DT this) (NN understanding))
          (PP (IN of)
            (NP
              (NP (DT the) (JJ novel) (NN mechanism))
              (VP (VBG underlying)
                (NP
                  (NP (NN conversion))
                  (PP (IN of)
                    (NP (NN CD4+CD25-) (NN T) (NNS cells)))
                  (PP (IN into)
                    (NP
                      (ADJP
                        (ADJP (JJ phenotypic))
                        (CC and)
                        (ADJP (JJ functional)))
                      (NN CD4+CD25+) (NNS Treg)))))))))
      (, ,)
      (NP
        (NP (DT the) (NN expansion))
        (PP (IN of)
          (NP (NN Treg)))
        (PP (IN for)
          (NP (JJ therapeutic) (NN consideration))))
      (VP (VBZ becomes)
        (NP (DT an) (JJ achievable) (NN goal))))
    (. .)))

(
  (S
    (S
      (PP (VBN Provided)
        (SBAR (IN that)
          (S
            (NP (DT the) (JJ regulatory) (NNS conditions))
            (VP (VBP are)
              (NP (NN met))))))
      (, ,)
      (NP (DT the) (VBN converted) (NN CD4+CD25+) (NNS Treg))
      (VP (VBP function)
        (PP (IN like)
          (NP (JJ conventional) (NN Treg)))
        (, ,)
        (ADVP (IN at) (JJS least) (FW in) (FW vitro))))
    (. .)))

(
  (S
    (SBAR (IN Although)
      (S
        (NP (PRP it))
        (VP (VBZ has)
          (ADVP (RB previously))
          (VP (VBN been)
            (VP (VBN shown)
              (SBAR (IN that)
                (S
                  (NP
                    (ADJP (RB naturally) (VBG occurring))
                    (NN CD4+CD25+) (NNS Treg))
                  (VP (VBP are)
                    (NP
                      (NP (JJ potent) (NNS inhibitors))
                      (PP (IN of)
                        (NP (JJ innate/adaptive) (NN immunity) (CD -LSB-61-63))))))))))
        (-RRB- -RSB-)))
    (, ,)
    (NP
      (NP
        (NP (NN induction))
        (PP (IN of)
          (NP
            (NP (DT a) (NN population))
            (PP (IN of)
              (NP (NN Treg))))))
      (CC and)
      (NP
        (NP (NN documentation))
        (PP (IN of)
          (NP (PRP$ their)
            (ADJP (FW in) (FW vivo))
            (NN potential)))))
    (VP (VBD was)
      (NP (DT an) (JJ important) (JJ next) (NN step)))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (NN pursuit))
          (PP (IN of)
            (NP (DT this) (NN goal)))))
      (, ,)
      (NP (JJ recent) (NNS studies))
      (VP (VBD demonstrated)
        (PP (IN for)
          (NP (DT the) (JJ first) (NN time)))
        (SBAR (IN that)
          (S
            (NP
              (NP (DT the) (NN transfer))
              (PP (IN of)
                (NP
                  (ADJP
                    (ADVP (FW in) (FW vitro))
                    (VBN generated))
                  (NN Treg)))
              (PP (IN into)
                (NP (NN disease) (NNS models))))
            (VP (VBZ does)
              (PP (IN in)
                (NP (NN fact)))
              (VP (VB ameliorate)
                (NP (NN pathogenesis) (CD -LSB-12) (-RRB- -RSB-))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Initially))
      (, ,)
      (NP (PRP it))
      (VP (VBD was)
        (VP (VBN shown)
          (SBAR (IN that)
            (S
              (NP
                (NP (JJ adoptive) (NN transfer))
                (PP (IN of)
                  (NP
                    (ADJP (FW in) (FW vitro))
                    (JJ TGF-β-converted) (NN Treg)))
                (PP
                  (ADVP (RB together))
                  (IN with)
                  (NP (JJ ovalbumin-specific) (NN TCR) (JJ transgenic) (NN T) (NNS cells))))
              (VP (VBD resulted)
                (PP (IN in)
                  (NP
                    (NP (DT a) (JJ profound) (NN inhibition))
                    (PP (IN of)
                      (NP
                        (NP (JJ antigen-specific) (NN expansion))
                        (PP (IN of)
                          (NP (JJ naive) (JJ CD4+) (JJ transgenic) (NN T) (NNS cells)))))))
                (ADVP (FW in) (FW vivo))))))))
    (. .)))

(
  (S
    (PP (IN Although)
      (NP (DT the) (JJ TGF-β-converted) (NN CD25+) (NN suppressor) (NN population)))
    (-LRB- -LRB-)
    (NP (NN DO11.10))))

(
  (S
    (S
      (S
        (NP
          (NP
            (ADJP (NN TCR) (JJ transgenic)))
          (PRN (, ,)
            (NP (JJ KJ1-26+))
            (-RRB- -RRB-)))
        (VP (VBN proliferated)
          (ADVP (FW in) (FW vivo))
          (PP (IN on)
            (NP
              (NP (NN immunization))
              (PP (IN with)
                (NP (NN ovalbumin) (NN peptide)))))))
      (, ,)
      (NP
        (NP (DT the) (VBN recovered) (JJ KJ1-26+) (JJ CD4+) (NN T) (NNS cells))
        (PP (IN from)
          (NP (JJ draining) (NN lymph) (NNS nodes))))
      (VP
        (VP (VBD remained)
          (ADJP (JJ unresponsive)
            (PP (TO to)
              (NP
                (NP (NN re-challenge))
                (PP (IN with)
                  (NP (NN ovalbumin) (NN peptide)))))
            (ADVP (FW in) (FW vitro))))
        (, ,)
        (VP (VBD produced)
          (NP (DT no) (JJ antigen-specific)
            (NP (NN IL-4))
            (CC and)
            (NP (NN IFN-γ))))
        (, ,)
        (CC and)
        (VP (VBD expressed)
          (NP
            (NP (JJ high) (NNS levels))
            (PP (IN of)
              (NP (NN CD25) (CD -LSB-12))))))
      (-RRB- -RSB-))
    (PRN (, ,)
      (NP (DT all)
        (ADJP (JJ consistent)
          (PP (IN with)
            (NP (JJ professional) (NN CD4+CD25+) (JJ regulatory) (NN T) (NNS cells))))
        (CD -LSB-64,65))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (ADVP (RB Moreover))
      (, ,)
      (PP (IN in)
        (NP
          (NP (DT a) (JJ dramatic) (NN turnaround))
          (PP (IN of)
            (NP (JJ allergen-induced) (JJ asthmatic) (NN lung) (NN disease)))))
      (, ,)
      (NP (JJ TGF-β-converted/induced) (NN Treg))
      (, ,)
      (SBAR
        (WHADVP (WRB when))
        (S
          (VP (VBN transferred)
            (PP (TO to)
              (NP (DT an) (JJ asthmatic) (NN mouse))))))
      (, ,)
      (VP (VBD suppressed)
        (NP
          (NP (JJ allergen-induced) (NN inflammation))
          (CC and)
          (NP (NN pathogenesis) (CD -LSB-12) (-RRB- -RSB-)))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (DT this) (NN model)))
      (, ,)
      (NP (NNS mice))
      (VP (VBP are)
        (VP
          (VP (VBN immunized)
            (PP (IN with)
              (NP (NN house) (NN dust) (JJ mite))))
          (CC and)
          (RB then)
          (VP (VBN challenged)
            (ADVP (RB intratracheally))
            (PP (IN with)
              (NP
                (NP (NN house) (NN dust) (JJ mite))
                (S
                  (VP (TO to)
                    (VP (VB induce)
                      (NP
                        (NP (NN airway) (NN hyperreactivity))
                        (, ,)
                        (NP (NN mucus) (NN accumulation))
                        (, ,)
                        (NP (NN eosinophilia))
                        (CC and)
                        (NP (NN IgE) (NN production))))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NN Delivery))
        (PP (IN of)
          (NP (NN Treg)))
        (PP (TO to)
          (NP (DT these) (JJ asthmatic) (NNS mice)))
        (PP (IN on)
          (NP (NN day) (CD 0)
            (CC and)
            (CD 14))))
      (VP (VBD was)
        (ADJP (JJ able)
          (S
            (VP (TO to)
              (VP (VB prevent)
                (NP
                  (NP (DT the) (JJ immunopathogenic) (NN response))
                  (PRN (-LRB- -LRB-)
                    (NP (NNP Fig.) (CD 2))
                    (-RRB- -RRB-)))))))
        (, ,)
        (S
          (VP (VBG confirming)
            (NP
              (NP (DT the) (JJ functional) (NNS prowess))
              (PP (IN of)
                (NP (DT these)
                  (ADJP (RB newly) (VBN converted))
                  (NNS cells))))
            (PP (IN in)
              (NP
                (NP (DT the) (NN suppression))
                (PP (IN of)
                  (NP
                    (NP
                      (ADJP (JJ inflammatory)))
                    (CC and)
                    (NP
                      (NP (JJ immune) (NNS responses))
                      (ADVP (FW in) (FW vivo)))))))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Treg))
      (PP (IN in)
        (NP (JJ autoimmune) (NNS diseases))))))

(
  (S
    (S
      (NP
        (NP (JJ Human)
          (NP
            (NP (JJ systemic) (NN lupus) (NN erythematosus))
            (PRN (-LRB- -LRB-)
              (NP (NN SLE))
              (-RRB- -RRB-)))
          (NNS patients))
        (CC and)
        (NP
          (NP (JJ murine) (NNS models))
          (PP (IN of)
            (NP (NN SLE)))))
      (VP (VBP manifest)
        (NP
          (NP (DT a) (JJ wide) (NN range))
          (PP (IN of)
            (NP (JJ immunological) (NNS abnormalities))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (DT The) (RBS most) (JJ pervasive))
        (PP (IN of)
          (NP (DT these))))
      (VP (VBP include)
        (NP
          (NP (DT the) (NN generation))
          (PP (IN of)
            (NP (JJ pathogenic) (NNS autoantibodies))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (DT this) (NN regard)))
    (, ,)
    (S
      (S
        (NP
          (NP (CD 98) (NN %))
          (PP (IN of)
            (NP (JJ human) (NN SLE) (NNS patients))))
        (VP (VBP possess)
          (NP (JJ antinuclear) (NNS antibodies))))
      (CC and)
      (S
        (NP
          (NP
            (QP (CD 50) (TO to) (CD 80))
            (NN %))
          (PP (IN of)
            (NP (DT these))))
        (VP (VBP have)
          (NP
            (NP (JJ anti-double-stranded) (NN DNA) (NNS antibodies))
            (, ,)
            (NP
              (NP (DT the) (NN result))
              (PP (IN of)
                (NP
                  (NP (JJ unchecked) (NN B) (NN lymphocyte) (NN activation))
                  (CC and)
                  (NP (NN antibody) (NN production)))))
            (, ,))
          (PP
            (ADVP (RB probably))
            (JJ due) (TO to)
            (NP (JJ uncontrolled) (NN T) (NN cell) (NNS hyper-responsiveness))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (CC Both)
          (NP (NN Th1))
          (CC and)
          (NP (NN Th2)))
        (NNS responses))
      (VP (VBP are)
        (VP (VBN elevated) (, ,)
          (SBAR (IN as)
            (S
              (VP (VBN demonstrated)
                (PP (IN by)
                  (NP
                    (NP
                      (NP (DT the) (NN upregulation))
                      (PP (IN of)
                        (NP
                          (NP (JJ proinflammatory) (NNS cytokines))
                          (, ,)
                          (ADJP (RB notably) (JJ IFN-γ))
                          (, ,)
                          (NP
                            (NP (NN IL-6))
                            (, ,)
                            (NP (NN IL-12))
                            (, ,)
                            (CC and)
                            (NP (NN IL-10)))
                          (, ,))))
                    (CONJP (RB as) (RB well) (IN as))
                    (NP
                      (ADJP (NN T) (JJ cell-dependent))
                      (NN autoantibody) (NN production))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Interestingly))
      (, ,)
      (NP (DT these)
        (NP
          (NP (NN T))
          (CC and)
          (NP (NN B)))
        (NN lymphocyte) (NNS abnormalities))
      (VP (VBP have)
        (VP (VBN been)
          (VP (VBN attributed) (, ,)
            (ADVP
              (ADVP (IN at) (JJS least))
              (RB partly))
            (, ,)
            (PP (TO to)
              (NP
                (NP
                  (NP (JJ defective) (NN production))
                  (CC and)
                  (NP (NN function)))
                (PP (IN of)
                  (NP (NN TGF-β) (CD -LSB-12,66))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (PP (IN In) (NN contrast) (TO to)
        (NP (JJ strong) (NNS suspicions)))
      (, ,)
      (NP (JJ few) (NNS data))
      (ADVP (RB yet))
      (VP (VBP exist)
        (PP (IN as) (TO to)
          (SBAR (IN whether)
            (S
              (NP
                (NP (DT the)
                  (NP (JJ uncontrolled) (NN T)
                    (CC and)
                    (NN B) (NN cell) (NN activation))
                  (CC and)
                  (NP (NN pathogenesis)))
                (PP (IN in)
                  (NP (NN SLE))))
              (VP (MD can)
                (VP (VB be)
                  (VP (VBN attributed)
                    (PP (TO to)
                      (NP
                        (NP (DT a) (NN deficiency))
                        (PP (IN in)
                          (NP (JJ CD4+CD25+) (JJ regulatory) (NN T) (NNS cells)))))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (DT this) (NN regard)))
    (, ,)
    (NP (CD one) (NN study))
    (VP (VBD indicated)
      (SBAR (IN that)
        (S
          (S
            (NP (JJ CD4+CD25+) (NN T) (NNS cells))
            (VP (VBD were)
              (ADVP (RB significantly))
              (VP (VBN decreased)
                (PP (IN in)
                  (NP
                    (NP (NNS patients))
                    (PP (IN with)
                      (NP (JJ active) (NN SLE)))))
                (PP (IN in)
                  (NP
                    (NP (NN comparison))
                    (PP (IN with)
                      (NP
                        (NP (JJ normal) (NNS subjects))
                        (CC and)
                        (NP (NNS patients))))
                    (PP (IN with)
                      (NP
                        (NP (DT an) (JJ inactive) (NN stage))
                        (PP (IN of)
                          (NP (DT the) (NN disease) (NN -LSB-67)))))
                    (-RRB- -RSB-))))))
          (, ,)
          (CC and)
          (S
            (PP (IN in)
              (NP (DT another) (JJ recent) (NN study)))
            (NP (CD -LSB-68) (-RRB- -RSB-) (NN Treg))
            (VP (VBD were)
              (VP (VBN reported)
                (S
                  (VP (TO to)
                    (VP (VB be)
                      (ADJP (JJ abnormal)
                        (PP (IN in)
                          (NP
                            (NP
                              (NP (NN number))
                              (, ,)
                              (NP (NN phenotype))
                              (, ,)
                              (CC and)
                              (NP (NN function)))
                            (PP (IN in)
                              (NP
                                (NP (NNS patients))
                                (PP (IN with)
                                  (NP (JJ active) (NN SLE)))))))))))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (NP
        (NP (DT the) (JJ exact) (NN role))
        (PP (IN of)
          (NP (DT the) (VBN decreased) (NN CD4+CD25+) (NN Treg) (NNS levels)))
        (PP (IN in)
          (NP
            (NP (DT the) (NN pathogenesis))
            (PP (IN of)
              (NP (NN SLE))))))
      (VP (VBZ awaits)
        (NP
          (NP (NN demonstration))
          (PP (IN of)
            (NP
              (NP (DT a) (JJ significant) (NN correlation))
              (PP (IN between)
                (NP
                  (NP
                    (NP (DT the) (NNS levels))
                    (PP (IN of)
                      (NP
                        (NP (NN CD4+CD25+) (NN Treg))
                        (CC and)
                        (NP (JJ inactive) (NN disease)))))
                  (CC or)
                  (NP (NN flare) (NN activity) (CD -LSB-69))))))))
      (-RRB- -RSB-))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP
          (NP (JJ rheumatoid) (NN arthritis))
          (PRN (-LRB- -LRB-)
            (NP (NN RA))
            (-RRB- -RRB-))))
      (, ,)
      (NP
        (NP (DT the) (NN relationship))
        (PP (IN between)
          (NP
            (NP
              (NP (JJ CD4+CD25+) (NN Treg))
              (CC and)
              (NP (JJ Th1-dependent) (NN pathogenesis)))
            (PP (IN of)
              (NP (DT the) (NN disease))))))
      (ADVP (RB also))
      (VP (VBZ remains)
        (PP (IN under)
          (NP (NN study)))))
    (. .)))

(
  (S
    (S
      (NP (PRP It))
      (VP (VBD was)
        (ADVP (RB recently))
        (VP (VBN suggested)
          (SBAR
            (LST (CD -LSB-70) (-RRB- -RSB-))
            (IN that)
            (S
              (NP
                (NP (DT no) (JJ significant) (NN difference))
                (PP (IN in)
                  (NP (JJ suppressive) (NN activity))))
              (VP (VBD was)
                (VP (VBN found)
                  (PP (IN between)
                    (NP
                      (NP (JJ CD4+CD25+) (NN T) (NNS cells))
                      (PP (IN from)
                        (NP
                          (NP (JJ peripheral) (NN blood))
                          (PP (IN of)
                            (NP
                              (NP (NN RA) (NNS patients))
                              (CC and)
                              (NP (JJ healthy) (NN control) (NNS subjects)))))))))
                (, ,)
                (SBAR (IN although)
                  (S
                    (NP (DT the) (NNS numbers))
                    (VP (MD may)
                      (VP (VB be)
                        (ADJP (RBR less) (JJ -LSB-25))))
                    (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Nonetheless))
      (, ,)
      (NP
        (NP (NN CD4+CD25+) (NN T) (NNS cells))
        (PP (IN from)
          (NP (JJ synovial) (NN fluid))))
      (ADVP (RB reportedly))
      (VP (VBD had)
        (NP (DT a)
          (ADJP (RB significantly) (JJR higher))
          (JJ suppressive) (NN activity))
        (PP (IN than)
          (NP
            (NP (DT those))
            (PP (IN in)
              (NP
                (NP (JJ peripheral) (NN blood))
                (PP (IN of)
                  (NP (NN RA) (NNS patients)))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB Notably))
      (, ,)
      (PP (IN despite)
        (NP
          (NP (DT the) (NN presence))
          (PP (IN of)
            (NP
              (NP (DT these)
                (ADJP (RB highly) (JJ functional))
                (NNS Treg))
              (PP (IN in)
                (NP (JJ synovial) (NN fluid)))))))
      (, ,)
      (NP (EX there))
      (VP (VBD was)
        (ADVP (RB still))
        (NP
          (NP (JJ ongoing) (NN inflammation))
          (PP (IN in)
            (NP (DT the) (NNS joints))))
        (, ,)
        (S
          (VP (VBG indicating)
            (NP
              (NP (DT the) (JJ complex) (NN picture))
              (PP (IN of)
                (NP (NN RA) (NN pathogenesis)))
              (, ,)
              (SBAR
                (WHNP (WDT which))
                (S
                  (VP (MD might)
                    (VP (VB reflect)
                      (NP
                        (NP (DT a) (JJ prominent) (NN imbalance))
                        (PP (IN between)
                          (NP
                            (ADJP
                              (ADJP (JJ regulatory))
                              (CC and)
                              (ADJP (JJ inflammatory)))
                            (NNS checkpoints)))))))))))))
    (. .)))

(
  (S
    (PP (IN In)
      (NP (DT an) (JJ encouraging) (JJ experimental) (NN therapy) (NN study)))
    (, ,)
    (NP
      (NP
        (NP
          (NP (NNS patients))
          (PP (IN with)
            (NP (NN RA)))
          (SBAR
            (WHNP (WP who))
            (S
              (VP (VBD were)
                (VP (VBN treated)
                  (PP (IN for)
                    (NP (CD 6) (NNS months)))
                  (PP (IN with)
                    (NP (JJ oral) (NN dnaJP1))))))))
        (, ,)
        (NP
          (NP (DT a) (NN peptide))
          (SBAR
            (WHNP (WDT that))
            (S
              (VP (VBZ induces)
                (NP (JJ proinflammatory) (NN T) (NN cell) (NNS responses))
                (PP (IN in)
                  (NP (JJ naive) (NN RA) (NNS patients)))))))
        (, ,))
      (VP (VBN manifested)))
    (VP (VBD increased)
      (NP (NN Foxp3+CD4+CD25+) (NN T) (NNS cells))
      (, ,)
      (S
        (VP (VBG suggesting)
          (SBAR (IN that)
            (S
              (NP (DT the) (NN treatment))
              (VP (VBD induced)
                (NP
                  (NP
                    (NP (DT the) (NN emergence))
                    (PRN (-LRB- -LRB-)
                      (NP (NN enhancement))
                      (-RRB- -RRB-)))
                  (PP (IN of)
                    (NP (NN T) (NNS cells))))
                (PP (IN with)
                  (NP
                    (NP (DT the) (JJ regulatory) (NN phenotype))
                    (CD -LSB-71) (-RRB- -RSB-)))))))))
    (. .)))

(
  (S
    (S
      (PP (IN In)
        (NP (JJ short)))
      (, ,)
      (PP (IN despite)
        (NP
          (NP (DT the) (JJ complex) (NN picture))
          (PP (IN of)
            (NP (NN Treg)))
          (PP (IN in)
            (NP (NN autoimmunity)))))
      (, ,)
      (NP (PRP it))
      (VP (MD can)
        (VP (VB be)
          (VP (VBN envisioned)
            (SBAR (IN that)
              (S
                (NP (PRP it))
                (VP (MD will)
                  (VP (VB become)
                    (ADJP (JJ feasible)
                      (S
                        (VP (TO to)
                          (VP (VB manipulate)
                            (NP (JJ regulatory) (NN T) (NNS cells))
                            (PP (IN for)
                              (NP (JJ therapeutic) (NN benefit)))))))))))))))
    (. .)))

(
  (S
    (PP (IN With)
      (NP (JJ continued) (NNS efforts)))
    (, ,)
    (NP
      (NP (DT a) (JJR better) (NN understanding))
      (CC and)
      (NP
        (ADJP (RBR more) (JJ advanced))
        (NNS techniques)))
    (VP (MD will)
      (VP (VB emerge)
        (PP (IN for)
          (NP
            (NP (DT the)
              (NP (NN induction))
              (CC and/or)
              (NP (NN expansion)))
            (PP (IN of)
              (NP (NN Treg)))))
        (S
          (VP (TO to)
            (VP (VB enhance)
              (NP
                (NP (PRP$ their) (NN role))
                (PP (IN in)
                  (NP
                    (NP (NN autoimmunity))
                    (, ,)
                    (NP (NN allergy))
                    (, ,)
                    (CC and)
                    (NP (NN graft) (NN rejection))))))))))
    (. .)))

(
  (S
    (NP (NN Conclusion))))

(
  (S
    (S
      (S
        (NP
          (ADJP
            (ADJP (JJ Innate))
            (CC and)
            (ADJP (JJ adaptive)))
          (JJ immune) (NNS responses))
        (VP (VBP are)
          (ADJP (JJ essential)
            (S
              (VP (TO to)
                (VP (VB protect)
                  (NP (DT the) (NN host))
                  (PP (IN from)
                    (NP
                      (NP (DT a) (NN plethora))
                      (PP (IN of)
                        (NP
                          (ADJP (RB potentially) (JJ pathogenic))
                          (NNS microorganisms)))))))))))
      (, ,)
      (CC but)
      (S
        (NP
          (NP (NNS countermeasures))
          (VP (TO to)
            (VP (VB prevent)
              (NP
                (NP (NN reactivity))
                (PP (IN of)
                  (NP (NN self)))))))
        (VP (VBP are)
          (ADVP (RB equally))
          (ADJP (JJ essential)))))
    (. .)))

(
  (S
    (S
      (SBAR (IN Although)
        (S
          (NP
            (NP (NN protection))
            (PP (IN against)
              (NP (JJ self-recognition-induced) (NN autoimmunity))))
          (VP (VBZ is)
            (VP (VBN accomplished)
              (PP (IN in)
                (NP (JJ large) (NN part)))
              (PP (IN by)
                (NP
                  (NP (DT the) (JJ central) (NN deletion))
                  (PP (IN of)
                    (NP (JJ autoreactive) (NN T) (NNS cells)))))
              (PP (IN during)
                (NP (JJ intrathymic) (NN development)))))))
      (, ,)
      (S
        (S
          (NP (DT this) (NN process))
          (VP (VBZ is) (RB not)
            (ADJP (JJ perfect))))
        (CC and)
        (S
          (NP (JJ self-reactive) (NNS escapees))
          (VP (MD can)
            (VP (NN wreak)
              (NP (NN havoc))
              (PP (IN on)
                (NP (DT the) (JJ immune) (NN system))))))))
    (. .)))

(
  (S
    (S
      (ADVP (RB However))
      (, ,)
      (PP (IN among)
        (NP
          (NP (DT the) (JJ backup) (NNS pathways))
          (PP (IN in)
            (NP (DT the) (NN periphery)
              (S
                (VP (TO to)
                  (VP (VB protect)
                    (NP (PRP us))
                    (PP (IN from)
                      (NP (NN self-destruction))))))))))
      (VP (VBP are)
        (NP
          (NP (NN deletion))
          (, ,)
          (NP (NN anergy))
          (, ,)
          (NP (NN ignorance))
          (, ,)
          (CC and)
          (NP (JJ active) (NN suppression)))))
    (. .)))

(
  (S
    (PP (IN Among)
      (NP (DT these)))
    (, ,)
    (NP (JJ current) (NN interest))
    (VP (VBZ has)
      (VP (VBN zeroed)
        (PRT (IN in))
        (PP (IN on)
          (NP
            (NP (JJ CD4+CD25+) (JJ regulatory) (NN T) (NNS cells))
            (, ,)
            (SBAR
              (WHNP (WDT which))
              (S
                (VP (MD can)
                  (ADVP (RB profoundly))
                  (VP (VBP suppress)
                    (NP (NN responder) (NN T) (NN cell)
                      (NP
                        (NP (NN proliferation))
                        (CC and)
                        (NP (NNS cytokines))))
                    (ADVP
                      (ADVP (FW in) (FW vitro))
                      (CC and)
                      (ADVP (FW in) (FW vivo)))))))))))
    (. .)))

(
  (S
    (S
      (S
        (ADVP (RB Originally))
        (VP (VBN considered)
          (NP
            (NP (DT an) (JJ exclusive) (NN product))
            (PP (IN of)
              (NP (DT the) (NN thymus))))))
      (, ,)
      (NP (JJ important) (JJ new) (NNS data))
      (VP (VBP indicate)
        (SBAR (IN that)
          (S
            (NP (DT these) (NNS cells))
            (VP (MD can)
              (VP (VB be)
                (VP
                  (VP (VBN generated)
                    (PP (IN from)
                      (NP (JJ peripheral) (JJ CD4+) (NN T) (NNS cells))))
                  (CC and)
                  (VP (VBN expanded)
                    (PP (IN for)
                      (NP (NN delivery)))
                    (PP (IN as)
                      (NP (DT a) (JJ cellular) (JJ therapeutic) (NN strategy)))))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Opportunities))
        (PP (TO to)
          (NP
            (NP (NN use) (NN suppressor) (NN T) (NN cell) (NNS populations))
            (PP (IN in)
              (NP
                (NP (DT the) (NN treatment))
                (PP (IN of)
                  (NP
                    (NP (JJ debilitating) (JJ autoimmune) (NNS diseases))
                    (, ,)
                    (NP (NN allergy))
                    (, ,)
                    (NP (JJ chronic) (JJ infectious) (NNS diseases))
                    (, ,)
                    (CC and)
                    (NP (NN transplant) (NN rejection)))))))))
      (VP
        (VP (VBP are)
          (ADVP (RB no) (RBR longer))
          (NP
            (NP (DT a) (NN dream))
            (PP (IN of)
              (NP (DT the) (JJ future)))))
        (CC but)
        (VP (VBP are)
          (NP (DT an) (VBG emerging) (NN reality)))))
    (. .)))

(
  (S
    (ADVP (RB Moreover))
    (, ,)
    (SBAR (IN as)
      (S
        (NP (PRP we))
        (VP (VBP illuminate)
          (NP
            (NP (DT the) (NNS mechanisms))
            (PP (IN of)
              (NP
                (NP (NN regulation))
                (PP (IN of)
                  (NP (DT these) (NNS Treg)))))))))
    (, ,)
    (NP (PRP it))
    (VP (MD might)
      (ADVP (RB also))
      (VP (VB become)
        (ADJP (JJ feasible)
          (S
            (VP (TO to)
              (VP
                (VP
                  (VP (VB diminish))
                  (, ,)
                  (CONJP (RB rather) (IN than))
                  (VP (VB augment)))
                (, ,)
                (NP (PRP$ their) (NN numbers/activity)
                  (S
                    (VP
                      (VP (TO to)
                        (VP (VB promote)
                          (NP
                            (NP (NN tumor) (NN rejection))
                            (CC and)
                            (NP (NN vaccine) (NNS responses)))))
                      (CC and/or)
                      (VP (TO to)
                        (VP (VB reverse)
                          (NP (NN immunodeficiency) (NNS diseases)))))))))))))
    (. .)))

(
  (S
    (NP (NNS Abbreviations))))

(
  (S
    (S
      (NP (NNS APCs))
      (VP (VBG =)
        (NP
          (NP (JJ antigen-presenting) (NNS cells))
          (: ;)
          (NP
            (NP
              (NP (NN IFN) (JJ =) (NN interferon))
              (: ;)
              (NP (NN IL) (JJ =) (NN interleukin))
              (: ;)
              (NP (NN LAP) (JJ =) (JJ latency-associated) (NN peptide))
              (: ;)
              (NP (NN RA) (JJ =) (JJ rheumatoid) (NN arthritis))
              (: ;)
              (NP (NN SLE) (JJ =) (JJ systemic) (NN lupus) (NN erythematosus))
              (: ;)
              (NP (NNP TβR)))
            (JJ =) (NN TGF-β) (NN receptor))
          (: ;)
          (NP (NN TCR) (JJ =) (NN T-cell) (NN receptor))
          (: ;)
          (NP (NN TGF) (JJ =) (NN transforming) (NN growth) (NN factor))
          (: ;)
          (NP (NN Th) (JJ =) (NN T) (NN helper) (NN cell))
          (: ;)
          (NP
            (NP (NN Treg) (JJ =) (JJ regulatory) (NN T) (NN cell))
            (PRN (-LRB- -LRB-)
              (NP (NN s))
              (-RRB- -RRB-)))
          (: ;)
          (NP (NN TSP) (JJ =) (NN thrombospondin)))))
    (. .)))

(
  (S
    (NP (VBG Competing) (NNS interests))))

(
  (S
    (S
      (NP (DT The) (NN author) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-))
      (VP (VB declare)
        (SBAR (IN that)
          (S
            (NP (PRP they))
            (VP (VBP have)
              (NP (DT no) (VBG competing) (NNS interests)))))))
    (. .)))

(
  (S
    (NP
      (NP (NN Figure))
      (CC and)
      (NP (NN Table))
      (NP (NNS captions)))))

(
  (S
    (S
      (NP
        (NP (NN Figure) (CD 1))
        (: :)
        (NP (JJ Regulatory) (NN T) (NNS cells)))
      (VP (VBP mediate)
        (NP
          (ADJP
            (ADJP (JJ inflammatory))
            (CC and)
            (ADJP (JJ immune)))
          (NNS reactions))))
    (. .)))

(
  (S
    (S
      (NP (NN CD4+CD25+) (NNS Treg))
      (VP (MD can)
        (VP (VB suppress)
          (NP
            (NP (NN CD4+CD25-) (NN T) (NN cell) (NNS responses))
            (PP (TO to)
              (NP (NNS antigens))))
          (PP (IN through)
            (NP
              (NP (DT a)
                (ADJP
                  (ADJP (JJ contact-dependent))
                  (, ,)
                  (ADJP (JJ antigen-nonspecific)))
                (NN mechanism))
              (VP (VBG involving)
                (NP (NN TGF-β))))))))
    (. .)))

(
  (S
    (S
      (NP (NN Treg))
      (VP (VBP suppress)
        (NP (NN CD4+CD25-) (NN responder) (NN T) (NN cell)
          (NP
            (NP (NN proliferation))
            (CC and)
            (NP (NN cytokine) (NN production))))
        (, ,)
        (S
          (VP (VBG reining)
            (PP (IN in)
              (NP
                (NP (NN Th1))
                (CC and/or)
                (NP (NN Th2))
                (NP (NN immunity))))))))
    (. .)))

(
  (S
    (S
      (PP (IN Without)
        (NP
          (NP (JJ adequate) (NN intercession))
          (PP (IN by)
            (NP (NN Treg)))))
      (, ,)
      (NP
        (ADJP
          (ADJP (JJ Th1-))
          (CC or)
          (ADJP (JJ Th2-dominated)))
        (NNS responses))
      (VP (MD may)
        (VP (VB become)
          (ADJP (JJ pathogenic)))))
    (. .)))

(
  (S
    (S
      (NP (NN Figure) (CD 2) (: :) (NN Treg))
      (VP (VBD expanded)
        (ADVP (FW in) (FW vitro))
        (VP (VB suppress)
          (NP (JJ allergen-induced) (NN asthma))
          (ADVP (FW in) (FW vivo)))))
    (. .)))

(
  (S
    (S
      (NP
        (NP (NNS Mice))
        (VP
          (VP (VBN sensitized)
            (PP (TO to)
              (NP (NN house) (NN dust)
                (NP
                  (ADJP (JJ mite)
                    (PRN (-LRB- -LRB-)
                      (NP (NN HDM))
                      (-RRB- -RRB-))
                    (PP (IN by)
                      (NP
                        (NP
                          (ADJP
                            (ADJP (JJ intraperitoneal))
                            (PRN (-LRB- -LRB-)
                              (NP (NN ip))
                              (-RRB- -RRB-)))
                          (NN injection))
                        (PP (IN with)
                          (NP (NN HDM)))
                        (PP (IN on)
                          (NP (NNS days) (CD 0)
                            (CC and)
                            (CD 7))))))))))
          (CC and)
          (VP
            (ADVP (RB then))
            (VBN challenged)
            (PP (IN by)
              (NP
                (NP (JJ intratracheal)
                  (PRN (-LRB- -LRB-)
                    (NP (PRP it))
                    (-RRB- -RRB-))
                  (NN injection))
                (PP (IN on)
                  (NP (NNS days) (CD 14)
                    (CC and)
                    (CD 21))))))))
      (VP (VBD were)
        (VP (VBN injected)
          (ADVP (RB intraperitoneally)
            (PP (IN on)
              (NP (NNS days) (CD 0)
                (CC and)
                (CD 14))))
          (PP (IN with)
            (NP (NN Treg))))))
    (. .)))

(
  (S
    (S
      (PP
        (NP (CD Three) (NNS days))
        (IN after)
        (NP
          (NP (DT the) (JJ second) (JJ intratracheal) (NN challenge))
          (PP (IN with)
            (NP (NN HDM)))))
      (, ,)
      (NP (DT the) (NNS lungs))
      (VP (VBD were)
        (VP (VBN assessed)
          (PP (IN for)
            (NP (NN histopathology)))
          (PP (IN by)
            (NP
              (NP (JJ periodic) (NN acid) (NN Schiff) (NN staining))
              (PP (IN for)
                (NP
                  (NP (NNS mucopolysaccharides))
                  (PRN (-LRB- -LRB-)
                    (NP (JJ red))
                    (-RRB- -RRB-)))))))))
    (. .)))

(
  (S
    (S
      (NP
        (NP
          (NP (JJ Inflammatory) (NN pathology))
          (CC and)
          (NP (NN mucin) (NN obstruction)))
        (PP (IN of)
          (NP (DT the) (NNS airways))))
      (VP (VBD were)
        (ADVP (RB strikingly))
        (VP (VBN reduced)
          (PP (IN in)
            (NP
              (NP (NNS mice))
              (VP (VBG receiving)
                (NP (NN Treg) (NN -LSB-12)))))))
      (-RRB- -RSB-))
    (. .)))

